{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:37:46Z","timestamp":1791812266935,"version":"4.3.4"},"reference-count":377,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40259-020-00419-w","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T16:06:48Z","timestamp":1587053208000},"page":"435-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology"],"prefix":"10.1007","volume":"34","author":[{"given":"Congcong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina M.","family":"\u00d6tjengerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Roewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Mejias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L. J.","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"419_CR1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the \u201chigh-hanging fruit\u201d. Nat Rev Drug Discov. 2018;17:197\u2013223.","journal-title":"Nat Rev Drug Discov."},{"key":"419_CR2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1074\/jbc.M209548200","volume":"278","author":"JP Richard","year":"2003","unstructured":"Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem. 2003;278:585\u201390.","journal-title":"J Biol Chem."},{"key":"419_CR3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4161\/mabs.29268","volume":"6","author":"ALJ Marschall","year":"2014","unstructured":"Marschall ALJ, Zhang C, Frenzel A, Schirrmann T, Hust M, Perez F, et al. Delivery of antibodies to the cytosol: debunking the myths. mAbs. 2014;6:943\u201356.","journal-title":"mAbs"},{"key":"419_CR4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4939-6539-7_14","volume":"1513","author":"ALJ Marschall","year":"2017","unstructured":"Marschall ALJ, Zhang C, Dubel S. Evaluating the delivery of proteins to the cytosol of mammalian cells. Methods Mol Biol. 2017;1513:201\u20138.","journal-title":"Methods Mol Biol"},{"key":"419_CR5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cell.2006.07.025","volume":"126","author":"LA Banaszynski","year":"2006","unstructured":"Banaszynski LA, Chen L-C, Maynard-Smith LA, Ooi AGL, Wandless TJ. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell. 2006;126:995\u20131004.","journal-title":"Cell"},{"key":"419_CR6","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s00018-019-03112-6","volume":"76","author":"S Roth","year":"2019","unstructured":"Roth S, Fulcher LJ, Sapkota GP. Advances in targeted degradation of endogenous proteins. Cell Mol Life Sci CMLS. 2019;76:2761\u201377.","journal-title":"Cell Mol Life Sci CMLS."},{"key":"419_CR7","doi-asserted-by":"crossref","first-page":"e1006780","DOI":"10.1371\/journal.pgen.1006780","volume":"13","author":"MA El-Brolosy","year":"2017","unstructured":"El-Brolosy MA, Stainier DYR. Genetic compensation: a phenomenon in search of mechanisms. PLoS Genet. 2017;13:e1006780.","journal-title":"PLoS Genet"},{"issue":"1692\u20131706","key":"419_CR8","first-page":"e18","volume":"171","author":"D Clift","year":"2017","unstructured":"Clift D, McEwan WA, Labzin LI, Konieczny V, Mogessie B, James LC, et al. A method for the acute and rapid degradation of endogenous proteins. Cell. 2017;171(1692\u20131706):e18.","journal-title":"Cell"},{"key":"419_CR9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1620\/tjem.230.103","volume":"230","author":"M Kato Kaneko","year":"2013","unstructured":"Kato Kaneko M, Ogasawara S, Kato Y. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations. Tohoku J Exp Med. 2013;230:103\u20139.","journal-title":"Tohoku J Exp Med"},{"key":"419_CR10","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1111\/febs.13295","volume":"282","author":"S Nowicki","year":"2015","unstructured":"Nowicki S, Gottlieb E. Oncometabolites: tailoring our genes. FEBS J. 2015;282:2796\u2013805.","journal-title":"FEBS J"},{"key":"419_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nsmb.1727","volume":"17","author":"A Kirchhofer","year":"2010","unstructured":"Kirchhofer A, Helma J, Schmidthals K, Frauer C, Cui S, Karcher A, et al. Modulation of protein properties in living cells using nanobodies. Nat Struct Mol Biol. 2010;17:133\u20138.","journal-title":"Nat Struct Mol Biol"},{"key":"419_CR12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nature06526","volume":"450","author":"JA Wells","year":"2007","unstructured":"Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007;450:1001\u20139.","journal-title":"Nature"},{"key":"419_CR13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.tips.2013.04.007","volume":"34","author":"AA Ivanov","year":"2013","unstructured":"Ivanov AA, Khuri FR, Fu H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci. 2013;34:393\u2013400.","journal-title":"Trends Pharmacol Sci"},{"key":"419_CR14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.coph.2013.05.009","volume":"13","author":"AP Higueruelo","year":"2013","unstructured":"Higueruelo AP, Jubb H, Blundell TL. Protein-protein interactions as druggable targets: recent technological advances. Curr Opin Pharmacol. 2013;13:791\u20136.","journal-title":"Curr Opin Pharmacol"},{"key":"419_CR15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3389\/fimmu.2017.01001","volume":"8","author":"I Trenevska","year":"2017","unstructured":"Trenevska I, Li D, Banham AH. Therapeutic antibodies against intracellular tumor antigens. Front Immunol. 2017;8:1001.","journal-title":"Front Immunol."},{"key":"419_CR16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature15712","volume":"527","author":"S Harmansa","year":"2015","unstructured":"Harmansa S, Hamaratoglu F, Affolter M, Caussinus E. Dpp spreading is required for medial but not for lateral wing disc growth. Nature. 2015;527:317\u201322.","journal-title":"Nature"},{"key":"419_CR17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1074\/mcp.M700342-MCP200","volume":"7","author":"U Rothbauer","year":"2008","unstructured":"Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso MC, Leonhardt H. A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol Cell Proteom. 2008;7:282\u20139.","journal-title":"Mol Cell Proteom"},{"key":"419_CR18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nmeth953","volume":"3","author":"U Rothbauer","year":"2006","unstructured":"Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods. 2006;3:887\u20139.","journal-title":"Nat Methods"},{"key":"419_CR19","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1038\/ncomms3660","volume":"4","author":"HD Herce","year":"2013","unstructured":"Herce HD, Deng W, Helma J, Leonhardt H, Cardoso MC. Visualization and targeted disruption of protein interactions in living cells. Nat Commun. 2013;4:2660.","journal-title":"Nat Commun."},{"key":"419_CR20","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1074\/mcp.TIR118.000914","volume":"17","author":"B-M Keller","year":"2018","unstructured":"Keller B-M, Maier J, Secker K-A, Egetemaier S-M, Parfyonova Y, Rothbauer U, et al. Chromobodies to quantify changes of endogenous protein concentration in living cells. Mol Cell Proteom. 2018;17:2518\u201333.","journal-title":"Mol Cell Proteom"},{"key":"419_CR21","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3390\/antib8010010","volume":"8","author":"B-M Keller","year":"2019","unstructured":"Keller B-M, Maier J, Weldle M, Segan S, Traenkle B, Rothbauer U. A strategy to optimize the generation of stable chromobody cell lines for visualization and quantification of endogenous proteins in living cells. Antibodies (Basel). 2019;8:E10.","journal-title":"Antibodies (Basel)."},{"key":"419_CR22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/19420862.2015.1076601","volume":"7","author":"ALJ Marschall","year":"2015","unstructured":"Marschall ALJ, D\u00fcbel S, B\u00f6ldicke T. Specific in vivo knockdown of protein function by intrabodies. mAbs. 2015;7:1010\u201335.","journal-title":"mAbs"},{"key":"419_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.3.1.14110","volume":"3","author":"ALJ Marschall","year":"2011","unstructured":"Marschall ALJ, Frenzel A, Schirrmann T, Schungel M, Dubel S. Targeting antibodies to the cytoplasm. mAbs. 2011;3:3\u201316.","journal-title":"mAbs"},{"key":"419_CR24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000479633","volume":"44","author":"A Frenzel","year":"2017","unstructured":"Frenzel A, Kugler J, Helmsing S, Meier D, Schirrmann T, Hust M, et al. Designing human antibodies by phage display. Transfus Med Hemother. 2017;44:312\u20138.","journal-title":"Transfus Med Hemother."},{"key":"419_CR25","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1128\/microbiolspec.AID-0028-2014","volume":"3","author":"J Sheehan","year":"2015","unstructured":"Sheehan J, Marasco WA. Phage and yeast display. Microbiol Spectr. 2015;3:1692\u20131706. (AID-0028-2014).","journal-title":"Microbiol Spectr."},{"key":"419_CR26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-61779-931-0_2","volume":"901","author":"CR Geyer","year":"2012","unstructured":"Geyer CR, McCafferty J, Dubel S, Bradbury ARM, Sidhu SS. Recombinant antibodies and in vitro selection technologies. Methods Mol Biol. 2012;901:11\u201332.","journal-title":"Methods Mol Biol"},{"key":"419_CR27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/bfgp\/1.2.204","volume":"1","author":"M He","year":"2002","unstructured":"He M, Taussig MJ. Ribosome display: cell-free protein display technology. Brief Funct Genom Proteom. 2002;1:204\u201312.","journal-title":"Brief Funct Genom Proteom."},{"key":"419_CR28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/biot.201100129","volume":"6","author":"J Lofblom","year":"2011","unstructured":"Lofblom J. Bacterial display in combinatorial protein engineering. Biotechnol J. 2011;6:1115\u201329.","journal-title":"Biotechnol J"},{"key":"419_CR29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.sbi.2007.08.012","volume":"17","author":"SA Gai","year":"2007","unstructured":"Gai SA, Wittrup KD. Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol. 2007;17:467\u201373.","journal-title":"Curr Opin Struct Biol"},{"key":"419_CR30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.sbi.2016.10.019","volume":"45","author":"D Konning","year":"2017","unstructured":"Konning D, Zielonka S, Grzeschik J, Empting M, Valldorf B, Krah S, et al. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol. 2017;45:10\u20136.","journal-title":"Curr Opin Struct Biol"},{"key":"419_CR31","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1110\/ps.34602","volume":"11","author":"M Dumoulin","year":"2002","unstructured":"Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LGJ, et al. Single-domain antibody fragments with high conformational stability. Protein Sci. 2002;11:500\u201315.","journal-title":"Protein Sci"},{"key":"419_CR32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molimm.2014.02.014","volume":"59","author":"JL Liu","year":"2014","unstructured":"Liu JL, Zabetakis D, Brown JC, Anderson GP, Goldman ER. Thermal stability and refolding capability of shark derived single domain antibodies. Mol Immunol. 2014;59:194\u20139.","journal-title":"Mol Immunol"},{"key":"419_CR33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","volume":"35","author":"S Stahl","year":"2017","unstructured":"Stahl S, Graslund T, Eriksson Karlstrom A, Frejd FY, Nygren P-A, Lofblom J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017;35:691\u2013712.","journal-title":"Trends Biotechnol"},{"key":"419_CR34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1042\/BST20150075","volume":"43","author":"M Valerio-Lepiniec","year":"2015","unstructured":"Valerio-Lepiniec M, Urvoas A, Chevrel A, Guellouz A, Ferrandez Y, Mesneau A, et al. The alphaRep artificial repeat protein scaffold: a new tool for crystallization and live cell applications. Biochem Soc Trans. 2015;43:819\u201324.","journal-title":"Biochem Soc Trans"},{"key":"419_CR35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","volume":"55","author":"A Pluckthun","year":"2015","unstructured":"Pluckthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55:489\u2013511.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"419_CR36","first-page":"95","volume":"352","author":"A Koide","year":"2007","unstructured":"Koide A, Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol. 2007;352:95\u2013109.","journal-title":"Methods Mol Biol"},{"key":"419_CR37","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/00000542-200310000-00029","volume":"99","author":"C-Y Lan","year":"2003","unstructured":"Lan C-Y, Tan P-H, Cheng J-T, Lu H-F, Lin M-W, Hsiao P-N, et al. Immunoneutralization of c-Fos using intrathecal antibody electroporation attenuates chronic constrictive injury-induced hyperalgesia and regulates preprodynorphin expression in rats. Anesthesiology. 2003;99:938\u201346.","journal-title":"Anesthesiology"},{"key":"419_CR38","unstructured":"ClinicalTrials.gov. Search result: gene therapy. https:\/\/clinicaltrials.gov\/ct2\/results?cond=%26term=%26type=%26rslt=%26age_v=%26gndr=%26intr=Gene+therapy+%26titles=%26outc=%26spons=%26lead=%26id=%26cntry=%26state=%26city=%26dist=%26locn=%26rsub=%26strd_s=%26strd_e=%26prcd_s=%26prcd_e=%26sfpd_s=%26sfpd_e=%26rfpd_s=%26rfpd_e=%26lupd_s=%26lupd_e=%26sort. Accessed 25 Mar 2020."},{"key":"419_CR39","unstructured":"US FDA. Approved cellular and gene therapy products. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. Accessed 25 Mar 2020."},{"key":"419_CR40","unstructured":"US FDA. IMLYGIC (talimogene laherparepvec). https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/imlygic-talimogene-laherparepvec. Accessed 25 Mar 2020."},{"key":"419_CR41","unstructured":"US FDA. Zolgensma. https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma. Accessed 25 Mar 2020."},{"key":"419_CR42","unstructured":"US FDA. Luxturna. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/luxturna. Accessed 25 Mar 2020."},{"key":"419_CR43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/cts.12466","volume":"10","author":"A Keeler","year":"2017","unstructured":"Keeler A, ElMallah M, Flotte T. Gene therapy 2017: progress and future directions. Clin Transl Sci. 2017;10:242\u20138.","journal-title":"Clin Transl Sci."},{"key":"419_CR44","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017;1:2348\u201360.","journal-title":"Blood Adv."},{"key":"419_CR45","unstructured":"US FDA. Kymriah (tisagenlecleucel). https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel. Accessed 25 Mar 2020."},{"key":"419_CR46","unstructured":"US FDA. YESCARTA (axicabtagene ciloleucel). https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel"},{"key":"419_CR47","unstructured":"European Medicines Agency. Strimvelis. EMEA\/H\/C\/003854. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/strimvelis. Accessed 25 Mar 2020."},{"key":"419_CR48","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/emmm.201202287","volume":"5","author":"KB Kaufmann","year":"2013","unstructured":"Kaufmann KB, Buning H, Galy A, Schambach A, Grez M. Gene therapy on the move. EMBO Mol Med. 2013;5:1642\u201361.","journal-title":"EMBO Mol Med."},{"key":"419_CR49","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/mt.2016.38","volume":"24","author":"EP Papapetrou","year":"2016","unstructured":"Papapetrou EP, Schambach A. Gene insertion into genomic safe harbors for human gene therapy. Mol Ther. 2016;24:678\u201384.","journal-title":"Mol Ther"},{"key":"419_CR50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","volume":"70","author":"XM Anguela","year":"2019","unstructured":"Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273\u201388.","journal-title":"Annu Rev Med"},{"key":"419_CR51","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/nbt1095-1110","volume":"13","author":"S Biocca","year":"1995","unstructured":"Biocca S, Ruberti F, Tafani M, Pierandrei-Amaldi P, Cattaneo A. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. Biotechnology (Nat Publ Co). 1995;13:1110\u20135.","journal-title":"Biotechnology (Nat Publ Co)"},{"key":"419_CR52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0962-8924(00)89019-4","volume":"5","author":"S Biocca","year":"1995","unstructured":"Biocca S, Cattaneo A. Intracellular immunization: antibody targeting to subcellular compartments. Trends Cell Biol. 1995;5:248\u201352.","journal-title":"Trends Cell Biol"},{"key":"419_CR53","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-3-642-01147-4_12","volume-title":"Antibody engineering","author":"A Cardinale","year":"2010","unstructured":"Cardinale A, Biocca S. Expressing intrabodies in mammalian cells. In: Kontermann R, D\u00fcbel S, editors. Antibody engineering. Berlin: Springer; 2010. p. 161\u201372. https:\/\/doi.org\/10.1007\/978-3-642-01147-4_12."},{"key":"419_CR54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat Rev Drug Discov. 2017;16:315\u201337.","journal-title":"Nat Rev Drug Discov."},{"key":"419_CR55","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Moxetumomab pasudotox: first global approval. Drugs. 2018;78:1763\u20137.","journal-title":"Drugs."},{"key":"419_CR56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jim.2008.10.012","volume":"341","author":"N Strebe","year":"2009","unstructured":"Strebe N, Guse A, Sch\u00fcngel M, Schirrmann T, Hafner M, Jostock T, et al. Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. J Immunol Methods. 2009;341:30\u201340.","journal-title":"J Immunol Methods"},{"key":"419_CR57","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.4161\/mabs.34377","volume":"6","author":"ALJ Marschall","year":"2014","unstructured":"Marschall ALJ, Single FN, Schlarmann K, Bosio A, Strebe N, van den Heuvel J, et al. Functional knock down of VCAM1 in mice mediated by endoplasmatic reticulum retained intrabodies. mAbs. 2014;6:1394\u2013401.","journal-title":"mAbs"},{"key":"419_CR58","doi-asserted-by":"crossref","first-page":"e0215062","DOI":"10.1371\/journal.pone.0215062","volume":"14","author":"K B\u00fcssow","year":"2019","unstructured":"B\u00fcssow K, Themann P, Luu S, Pentrowski P, Harting C, Majewski M, et al. ER intrabody-mediated inhibition of interferon alpha secretion by mouse macrophages and dendritic cells. PLoS One. 2019;14:e0215062.","journal-title":"PLoS One"},{"key":"419_CR59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.csbj.2016.07.003","volume":"14","author":"ALJ Marschall","year":"2016","unstructured":"Marschall ALJ, D\u00fcbel S. Antibodies inside of a cell can change its outside: can intrabodies provide a new therapeutic paradigm? Comput Struct Biotechnol J. 2016;14:304\u20138.","journal-title":"Comput Struct Biotechnol J."},{"key":"419_CR60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-32805-8_5","volume":"917","author":"ALJ Marschall","year":"2015","unstructured":"Marschall ALJ, Dubel S, Boldicke T. Recent advances with ER targeted intrabodies. Adv Exp Med Biol. 2015;917:77\u201393.","journal-title":"Adv Exp Med Biol"},{"key":"419_CR61","doi-asserted-by":"crossref","first-page":"e41768","DOI":"10.7554\/eLife.41768","volume":"8","author":"LM Traub","year":"2019","unstructured":"Traub LM. A nanobody-based molecular toolkit provides new mechanistic insight into clathrin-coat initiation. eLife. 2019;8:e41768.","journal-title":"eLife."},{"key":"419_CR62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12915-019-0662-4","volume":"17","author":"DL Prole","year":"2019","unstructured":"Prole DL, Taylor CW. A genetically encoded toolkit of functionalized nanobodies against fluorescent proteins for visualizing and manipulating intracellular signalling. BMC Biol. 2019;17:41.","journal-title":"BMC Biol"},{"key":"419_CR63","doi-asserted-by":"crossref","first-page":"31177","DOI":"10.1038\/srep31177","volume":"6","author":"E Beghein","year":"2016","unstructured":"Beghein E, Van Audenhove I, Zwaenepoel O, Verhelle A, De Ganck A, Gettemans J. A new survivin tracer tracks, delocalizes and captures endogenous survivin at different subcellular locations and in distinct organelles. Sci Rep. 2016;6:31177.","journal-title":"Sci Rep."},{"key":"419_CR64","first-page":"1045","volume":"10","author":"A Steels","year":"2018","unstructured":"Steels A, Verhelle A, Zwaenepoel O, Gettemans J. Intracellular displacement of p53 using transactivation domain (p53 TAD) specific nanobodies. mAbs. 2018;10:1045\u201359.","journal-title":"mAbs."},{"key":"419_CR65","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/mt.2015.178","volume":"23","author":"PR Moody","year":"2015","unstructured":"Moody PR, Sayers EJ, Magnusson JP, Alexander C, Borri P, Watson P, et al. Receptor crosslinking: a general method to trigger internalization and lysosomal targeting of therapeutic receptor:ligand complexes. Mol Ther J. 2015;23:1888\u201398.","journal-title":"Mol Ther J."},{"key":"419_CR66","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1038\/s41598-019-42456-8","volume":"9","author":"SG Patel","year":"2019","unstructured":"Patel SG, Sayers EJ, He L, Narayan R, Williams TL, Mills EM, et al. Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines. Sci Rep. 2019;9:6298.","journal-title":"Sci Rep."},{"key":"419_CR67","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/jacs.5b00620","volume":"137","author":"RE Wang","year":"2015","unstructured":"Wang RE, Liu T, Wang Y, Cao Y, Du J, Luo X, et al. An immunosuppressive antibody\u2013drug conjugate. J Am Chem Soc. 2015;137:3229\u201332.","journal-title":"J Am Chem Soc"},{"key":"419_CR68","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature16057","volume":"527","author":"SM Lehar","year":"2015","unstructured":"Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, et al. Novel antibody\u2013antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527:323\u20138.","journal-title":"Nature."},{"key":"419_CR69","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","volume":"57","author":"JM Lambert","year":"2014","unstructured":"Lambert JM, Chari RVJ. Ado-trastuzumab Emtansine (T-DM1): an antibody\u2013drug conjugate (ADC). J Med Chem. 2014;57:6949\u201364.","journal-title":"J Med Chem"},{"key":"419_CR70","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","volume":"66","author":"HK Erickson","year":"2006","unstructured":"Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66:4426\u201333.","journal-title":"Cancer Res"},{"key":"419_CR71","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert JM, Morris CQ. Antibody\u2013drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34:1015\u201335.","journal-title":"Adv Ther."},{"key":"419_CR72","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40259-017-0254-1","volume":"31","author":"PM Drake","year":"2017","unstructured":"Drake PM, Rabuka D. Recent developments in ADC technology: preclinical studies signal future clinical trends. BioDrugs. 2017;31:521\u201331.","journal-title":"BioDrugs."},{"key":"419_CR73","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/toxins9110344","volume":"9","author":"A Rust","year":"2017","unstructured":"Rust A, Partridge LJ, Davletov B, Hautbergue GM. The use of plant-derived ribosome inactivating proteins in immunotoxin development: past, present and future generations. Toxins. 2017;9:344.","journal-title":"Toxins."},{"key":"419_CR74","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1021\/bc970192w","volume":"9","author":"F Dosio","year":"1998","unstructured":"Dosio F, Arpicco S, Adobati E, Canevari S, Brusa P, De Santis R, et al. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins. Bioconjug Chem. 1998;9:372\u201381.","journal-title":"Bioconjug Chem"},{"key":"419_CR75","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1021\/acs.bioconjchem.5b00190","volume":"26","author":"JE Weldon","year":"2015","unstructured":"Weldon JE, Skarzynski M, Therres JA, Ostovitz JR, Zhou H, Kreitman RJ, et al. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A. Bioconjug Chem. 2015;26:1120\u20138.","journal-title":"Bioconjug Chem"},{"key":"419_CR76","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1042\/bst0311260","volume":"31","author":"JM Lord","year":"2003","unstructured":"Lord JM, Deeks E, Marsden CJ, Moore K, Pateman C, Smith DC, et al. Retrograde transport of toxins across the endoplasmic reticulum membrane. Biochem Soc Trans. 2003;31:1260\u20132.","journal-title":"Biochem Soc Trans"},{"key":"419_CR77","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0014-5793(99)01222-3","volume":"459","author":"JC Simpson","year":"1999","unstructured":"Simpson JC, Roberts LM, Romisch K, Davey J, Wolf DH, Lord JM. Ricin A chain utilises the endoplasmic reticulum-associated protein degradation pathway to enter the cytosol of yeast. FEBS Lett. 1999;459:80\u20134.","journal-title":"FEBS Lett"},{"key":"419_CR78","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1021\/bi011580v","volume":"41","author":"ED Deeks","year":"2002","unstructured":"Deeks ED, Cook JP, Day PJ, Smith DC, Roberts LM, Lord JM. The low lysine content of ricin A chain reduces the risk of proteolytic degradation after translocation from the endoplasmic reticulum to the cytosol. Biochemistry. 2002;41:3405\u201313.","journal-title":"Biochemistry"},{"key":"419_CR79","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1073\/pnas.0809013105","volume":"105","author":"RA Spooner","year":"2008","unstructured":"Spooner RA, Hart PJ, Cook JP, Pietroni P, Rogon C, H\u00f6hfeld J, et al. Cytosolic chaperones influence the fate of a toxin dislocated from the endoplasmic reticulum. Proc Natl Acad Sci USA. 2008;105:17408\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR80","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.2014-0358","volume":"20","author":"C Alewine","year":"2015","unstructured":"Alewine C, Hassan R, Pastan I. Advances in anticancer immunotoxin therapy. Oncologist. 2015;20:176\u201385.","journal-title":"Oncologist."},{"key":"419_CR81","doi-asserted-by":"crossref","first-page":"16556","DOI":"10.1073\/pnas.1218219110","volume":"110","author":"B Sehnert","year":"2013","unstructured":"Sehnert B, Burkhardt H, Wessels JT, Schroder A, May MJ, Vestweber D, et al. NF-kappaB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-kappaB in immune-mediated diseases. Proc Natl Acad Sci USA. 2013;110:16556\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR82","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/978-1-4939-2422-6_33","volume":"1280","author":"B Sehnert","year":"2015","unstructured":"Sehnert B, Burkhardt H, Dubel S, Voll RE. The \u201csneaking-ligand\u201d approach: cell-type specific inhibition of the classical. Methods Mol Biol. 2015;1280:559\u201378.","journal-title":"Methods Mol Biol"},{"key":"419_CR83","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymeth.2004.04.004","volume":"34","author":"AA der Maur","year":"2004","unstructured":"der Maur AA, Tissot K, Barberis A. Antigen-independent selection of intracellular stable antibody frameworks. Methods. 2004;34:215\u201324.","journal-title":"Methods."},{"key":"419_CR84","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ymeth.2004.04.008","volume":"34","author":"M Visintin","year":"2004","unstructured":"Visintin M, Quondam M, Cattaneo A. The intracellular antibody capture technology: towards the high-throughput selection of functional intracellular antibodies for target validation. Methods. 2004;34:200\u201314.","journal-title":"Methods"},{"key":"419_CR85","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41467-019-13654-9","volume":"11","author":"H Kabayama","year":"2020","unstructured":"Kabayama H, Takeuchi M, Tokushige N, Muramatsu S, Kabayama M, Fukuda M, et al. An ultra-stable cytoplasmic antibody engineered for in vivo applications. Nat Commun. 2020;11:336.","journal-title":"Nat Commun."},{"key":"419_CR86","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/emboj\/cdg106","volume":"22","author":"T Tanaka","year":"2003","unstructured":"Tanaka T, Rabbitts TH. Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J. 2003;22:1025\u201335.","journal-title":"EMBO J"},{"key":"419_CR87","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2004.04.062","volume":"340","author":"FA da Silva","year":"2004","unstructured":"da Silva FA, Santa-Marta M, Freitas-Vieira A, Mascarenhas P, Barahona I, Moniz-Pereira J, et al. Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J Mol Biol. 2004;340:525\u201342.","journal-title":"J Mol Biol."},{"key":"419_CR88","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jmb.2005.07.038","volume":"352","author":"D Saerens","year":"2005","unstructured":"Saerens D, Pellis M, Loris R, Pardon E, Dumoulin M, Matagne A, et al. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol. 2005;352:597\u2013607.","journal-title":"J Mol Biol"},{"key":"419_CR89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/jmbi.2002.5392","volume":"317","author":"M Visintin","year":"2002","unstructured":"Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002;317:73\u201383.","journal-title":"J Mol Biol"},{"key":"419_CR90","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jmb.2007.11.085","volume":"376","author":"T Tanaka","year":"2008","unstructured":"Tanaka T, Rabbitts TH. Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds. J Mol Biol. 2008;376:749\u201357.","journal-title":"J Mol Biol"},{"key":"419_CR91","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/pro.3154","volume":"26","author":"T Boldicke","year":"2017","unstructured":"Boldicke T. Single domain antibodies for the knockdown of cytosolic and nuclear proteins. Protein Sci. 2017;26:925\u201345.","journal-title":"Protein Sci"},{"key":"419_CR92","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/2472555219853235","volume":"24","author":"J Woods","year":"2019","unstructured":"Woods J. Selection of functional intracellular nanobodies. SLAS Discov. 2019;24:703\u201313.","journal-title":"SLAS Discov."},{"key":"419_CR93","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzq022","volume":"23","author":"E Kvam","year":"2010","unstructured":"Kvam E, Sierks MR, Shoemaker CB, Messer A. Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. Protein Eng Des Sel PEDS. 2010;23:489\u201398.","journal-title":"Protein Eng Des Sel PEDS."},{"key":"419_CR94","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2013.04.017","volume":"78","author":"GG Gross","year":"2013","unstructured":"Gross GG, Junge JA, Mora RJ, Kwon H-B, Olson CA, Takahashi TT, et al. Recombinant probes for visualizing endogenous synaptic proteins in living neurons. Neuron. 2013;78:971\u201385.","journal-title":"Neuron"},{"key":"419_CR95","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jmb.2008.10.051","volume":"385","author":"AC Fisher","year":"2009","unstructured":"Fisher AC, DeLisa MP. Efficient isolation of soluble intracellular single-chain antibodies using the twin-arginine translocation machinery. J Mol Biol. 2009;385:299\u2013311.","journal-title":"J Mol Biol"},{"key":"419_CR96","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.abb.2012.04.023","volume":"526","author":"M Pellis","year":"2012","unstructured":"Pellis M, Pardon E, Zolghadr K, Rothbauer U, Vincke C, Kinne J, et al. A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies. Arch Biochem Biophys. 2012;526:114\u201323.","journal-title":"Arch Biochem Biophys"},{"key":"419_CR97","doi-asserted-by":"crossref","first-page":"e1800350","DOI":"10.1002\/biot.201800350","volume":"14","author":"TD Nguyen","year":"2019","unstructured":"Nguyen TD, Nagamune T, Kawahara M. A suicide switch directly eliminates intracellular scFv oligomers in the cytoplasm of mammalian cells. Biotechnol J. 2019;14:e1800350.","journal-title":"Biotechnol J"},{"key":"419_CR98","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41467-018-03984-5","volume":"9","author":"V Siciliano","year":"2018","unstructured":"Siciliano V, DiAndreth B, Monel B, Beal J, Huh J, Clayton KL, et al. Engineering modular intracellular protein sensor-actuator devices. Nat Commun. 2018;9:1881.","journal-title":"Nat Commun."},{"key":"419_CR99","doi-asserted-by":"crossref","first-page":"13194","DOI":"10.1038\/s41598-017-13469-y","volume":"7","author":"WPR Verdurmen","year":"2017","unstructured":"Verdurmen WPR, Mazlami M, Pl\u00fcckthun A. A quantitative comparison of cytosolic delivery via different protein uptake systems. Sci Rep. 2017;7:13194.","journal-title":"Sci Rep."},{"key":"419_CR100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature19764","volume":"538","author":"MP Stewart","year":"2016","unstructured":"Stewart MP, Sharei A, Ding X, Sahay G, Langer R, Jensen KF. In vitro and ex vivo strategies for intracellular delivery. Nature. 2016;538:183\u201392.","journal-title":"Nature"},{"key":"419_CR101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1208\/s12248-008-9071-2","volume":"11","author":"A El-Sayed","year":"2009","unstructured":"El-Sayed A, Futaki S, Harashima H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 2009;11:13\u201322.","journal-title":"AAPS J"},{"key":"419_CR102","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acs.bioconjchem.8b00778","volume":"30","author":"D Pei","year":"2019","unstructured":"Pei D, Buyanova M. Overcoming endosomal entrapment in drug delivery. Bioconjug Chem. 2019;30:273\u201383.","journal-title":"Bioconjug Chem"},{"key":"419_CR103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41377-018-0048-3","volume":"7","author":"J Liu","year":"2018","unstructured":"Liu J, Xiong R, Brans T, Lippens S, Parthoens E, Zanacchi FC, et al. Repeated photoporation with graphene quantum dots enables homogeneous labeling of live cells with extrinsic markers for fluorescence microscopy. Light Sci Appl. 2018;7:47.","journal-title":"Light Sci Appl."},{"key":"419_CR104","doi-asserted-by":"crossref","unstructured":"Blanco-Toribio A, Muyldermans S, Frankel G, Fernandez LA. Direct injection of functional single-domain antibodies from E. coli into human cells. PloS One. 2010;5:e15227.","DOI":"10.1371\/journal.pone.0015227"},{"key":"419_CR105","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4161\/mabs.25084","volume":"5","author":"G Freund","year":"2013","unstructured":"Freund G, Sibler A-P, Desplancq D, Oulad-Abdelghani M, Vigneron M, Gannon J, et al. Targeting endogenous nuclear antigens by electrotransfer of monoclonal antibodies in living cells. mAbs. 2013;5:518\u201322.","journal-title":"mAbs"},{"key":"419_CR106","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1021\/acs.chemrev.7b00678","volume":"118","author":"MP Stewart","year":"2018","unstructured":"Stewart MP, Langer R, Jensen KF. Intracellular delivery by membrane disruption: mechanisms, strategies, and concepts. Chem Rev. 2018;118:7409\u2013531.","journal-title":"Chem Rev"},{"key":"419_CR107","doi-asserted-by":"crossref","first-page":"15494","DOI":"10.1016\/S0021-9258(19)84857-3","volume":"264","author":"R Chakrabarti","year":"1989","unstructured":"Chakrabarti R, Wylie DE, Schuster SM. Transfer of monoclonal antibodies into mammalian cells by electroporation. J Biol Chem. 1989;264:15494\u2013500.","journal-title":"J Biol Chem"},{"key":"419_CR108","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1083\/jcb.201709153","volume":"217","author":"S Conic","year":"2018","unstructured":"Conic S, Desplancq D, Ferrand A, Fischer V, Heyer V, Reina S, Martin B, et al. Imaging of native transcription factors and histone phosphorylation at high resolution in live cells. J Cell Biol. 2018;217:1537\u201352.","journal-title":"J Cell Biol."},{"key":"419_CR109","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nmeth.1401","volume":"6","author":"K Nishimura","year":"2009","unstructured":"Nishimura K, Fukagawa T, Takisawa H, Kakimoto T, Kanemaki M. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nat Methods. 2009;6:917\u201322.","journal-title":"Nat Methods"},{"key":"419_CR110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nchembio.1869","volume":"11","author":"HK Chung","year":"2015","unstructured":"Chung HK, Jacobs CL, Huo Y, Yang J, Krumm SA, Plemper RK, et al. Tunable and reversible drug control of protein production via a self-excising degron. Nat Chem Biol. 2015;11:713\u201320.","journal-title":"Nat Chem Biol"},{"key":"419_CR111","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/acschembio.6b00234","volume":"11","author":"R Navarro","year":"2016","unstructured":"Navarro R, Chen L-C, Rakhit R, Wandless TJ. A novel destabilizing domain based on a small-molecule dependent fluorophore. ACS Chem Biol. 2016;11:2101\u20134.","journal-title":"ACS Chem Biol"},{"key":"419_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00043-6","author":"A Mullard","year":"2019","unstructured":"Mullard A. First targeted protein degrader hits the clinic. Nat Rev Drug Discov. 2019. https:\/\/doi.org\/10.1038\/d41573-019-00043-6.","journal-title":"Nat Rev Drug Discov"},{"key":"419_CR113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","volume":"31","author":"M Pettersson","year":"2019","unstructured":"Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs)\u2014past, present and future. Drug Discov Today Technol. 2019;31:15\u201327.","journal-title":"Drug Discov Today Technol."},{"key":"419_CR114","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838\u201347.","journal-title":"Drug Discov Today."},{"key":"419_CR115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","volume":"37","author":"Y Zou","year":"2019","unstructured":"Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. Cell Biochem Funct. 2019;37:21\u201330.","journal-title":"Cell Biochem Funct"},{"key":"419_CR116","first-page":"377","volume":"8","author":"C Caruso","year":"2018","unstructured":"Caruso C. Arvinas, Pfizer team up on PROTACs. Cancer Discov. 2018;8:377\u20138.","journal-title":"Cancer Discov"},{"key":"419_CR117","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41422-019-0144-9","volume":"29","author":"J Guo","year":"2019","unstructured":"Guo J, Liu J, Wei W. Degrading proteins in animals: \u201cPROTAC\u201dtion goes in vivo. Cell Res. 2019;29:179\u201380.","journal-title":"Cell Res"},{"key":"419_CR118","unstructured":"Arvinas Inc. a phase 1 clinical trial of ARV-110 in patients with metastatic castration-resistant prostate cancer (mCRPC) [ClinicalTrials.gov identifier NCT03888612]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03888612. Accessed 25 Mar 2020."},{"key":"419_CR119","first-page":"145","volume":"2","author":"PD Burbelo","year":"2010","unstructured":"Burbelo PD, Ching KH, Han BL, Bush ER, Reeves WH, Iadarola MJ. Extraordinary antigenicity of the human Ro52 autoantigen. Am J Transl Res. 2010;2:145\u201355.","journal-title":"Am J Transl Res."},{"key":"419_CR120","doi-asserted-by":"crossref","first-page":"19985","DOI":"10.1073\/pnas.1014074107","volume":"107","author":"DL Mallery","year":"2010","unstructured":"Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA. 2010;107:19985\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR121","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1101\/gad.605910","volume":"24","author":"K Tachibana-Konwalski","year":"2010","unstructured":"Tachibana-Konwalski K, Godwin J, van der Weyden L, Champion L, Kudo NR, Adams DJ, et al. Rec8-containing cohesin maintains bivalents without turnover during the growing phase of mouse oocytes. Genes Dev. 2010;24:2505\u201316.","journal-title":"Genes Dev"},{"key":"419_CR122","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cub.2015.12.073","volume":"26","author":"S Burkhardt","year":"2016","unstructured":"Burkhardt S, Borsos M, Szydlowska A, Godwin J, Williams SA, Cohen PE, et al. Chromosome cohesion established by Rec8-cohesin in fetal oocytes is maintained without detectable turnover in oocytes arrested for months in mice. Curr Biol. 2016;26:678\u201385.","journal-title":"Curr Biol"},{"key":"419_CR123","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/0471140864.ps3002s73","volume":"73","author":"E Caussinus","year":"2013","unstructured":"Caussinus E, Kanca O, Affolter M. Protein knockouts in living eukaryotes using deGradFP and green fluorescent protein fusion targets. Curr Protoc Protein Sci. 2013;73:30\u20132.","journal-title":"Curr Protoc Protein Sci."},{"key":"419_CR124","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1242\/dev.148940","volume":"144","author":"A Ochoa-Espinosa","year":"2017","unstructured":"Ochoa-Espinosa A, Harmansa S, Caussinus E, Affolter M. Myosin II is not required for Drosophila tracheal branch elongation and cell intercalation. Development. 2017;144:2961\u20138.","journal-title":"Development."},{"key":"419_CR125","doi-asserted-by":"crossref","first-page":"dev148874","DOI":"10.1242\/dev.148874","volume":"145","author":"S Harmansa","year":"2018","unstructured":"Harmansa S, Affolter M. Protein binders and their applications in developmental biology. Development. 2018;145:dev148874.","journal-title":"Development"},{"key":"419_CR126","doi-asserted-by":"crossref","first-page":"e43125","DOI":"10.7554\/eLife.43125","volume":"8","author":"N Yamaguchi","year":"2019","unstructured":"Yamaguchi N, Colak-Champollion T, Knaut H. zGrad is a nanobody-based degron system that inactivates proteins in zebrafish. eLife. 2019;8:e43125.","journal-title":"eLife."},{"key":"419_CR127","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1074\/jbc.M113.544825","volume":"289","author":"AD Portnoff","year":"2014","unstructured":"Portnoff AD, Stephens EA, Varner JD, DeLisa MP. Ubiquibodies, synthetic E3 ubiquitin ligases endowed with unnatural substrate specificity for targeted protein silencing. J Biol Chem. 2014;289:7844\u201355.","journal-title":"J Biol Chem"},{"key":"419_CR128","doi-asserted-by":"crossref","first-page":"14269","DOI":"10.1038\/srep14269","volume":"5","author":"YJ Shin","year":"2015","unstructured":"Shin YJ, Park SK, Jung YJ, Kim YN, Kim KS, Park OK, et al. Nanobody-targeted E3-ubiquitin ligase complex degrades nuclear proteins. Sci Rep. 2015;5:14269.","journal-title":"Sci Rep."},{"key":"419_CR129","doi-asserted-by":"crossref","first-page":"170066","DOI":"10.1098\/rsob.170066","volume":"7","author":"LJ Fulcher","year":"2017","unstructured":"Fulcher LJ, Hutchinson LD, Macartney TJ, Turnbull C, Sapkota GP. Targeting endogenous proteins for degradation through the affinity-directed protein missile system. Open Biol. 2017;7:170066.","journal-title":"Open Biol."},{"key":"419_CR130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","volume":"4","author":"D Chatterjee","year":"2018","unstructured":"Chatterjee D, Bhatt M, Butler D, De Genst E, Dobson CM, Messer A, et al. Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson\u2019s disease model. NPJ Parkinsons Dis. 2018;4:25.","journal-title":"NPJ Parkinsons Dis."},{"key":"419_CR131","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1038\/s41467-018-05855-5","volume":"9","author":"K Daniel","year":"2018","unstructured":"Daniel K, Icha J, Horenburg C, Muller D, Norden C, Mansfeld J. Conditional control of fluorescent protein degradation by an auxin-dependent nanobody. Nat Commun. 2018;9:3297.","journal-title":"Nat Commun."},{"issue":"1544\u20131558","key":"419_CR132","first-page":"e6","volume":"26","author":"N Bery","year":"2019","unstructured":"Bery N, Keller L, Soulie M, Gence R, Iscache A-L, Cherier J, et al. A targeted protein degradation cell-based screening for nanobodies selective toward the cellular RHOB GTP-bound conformation. Cell Chem Biol. 2019;26(1544\u20131558):e6.","journal-title":"Cell Chem Biol."},{"key":"419_CR133","doi-asserted-by":"crossref","first-page":"e29199","DOI":"10.1371\/journal.pone.0029199","volume":"6","author":"DC Butler","year":"2011","unstructured":"Butler DC, Messer A. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One. 2011;6:e29199.","journal-title":"PLoS One"},{"key":"419_CR134","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1038\/s41598-018-24463-3","volume":"8","author":"Y Tamaki","year":"2018","unstructured":"Tamaki Y, Shodai A, Morimura T, Hikiami R, Minamiyama S, Ayaki T, et al. Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals. Sci Rep. 2018;8:6030.","journal-title":"Sci Rep."},{"key":"419_CR135","doi-asserted-by":"crossref","unstructured":"Banik S, Pedram K, Wisnovsky S, Riley N, Bertozzi C. Lysosome targeting chimeras (LYTACs) for the degradation of secreted and membrane proteins. ChemRxiv Preprint. 2019. https:\/\/chemrxiv.org\/articles\/Lysosome_Targeting_Chimeras_LYTACs_for_the_Degradation_of_Secreted_and_Membrane_Proteins\/7927061\/1. Accessed 17 Mar 2020.","DOI":"10.26434\/chemrxiv.7927061"},{"key":"419_CR136","doi-asserted-by":"crossref","first-page":"20007","DOI":"10.1074\/jbc.M112.355107","volume":"287","author":"L Vecchi","year":"2012","unstructured":"Vecchi L, Petris G, Bestagno M, Burrone OR. Selective targeting of proteins within secretory pathway for endoplasmic reticulum-associated degradation. J Biol Chem. 2012;287:20007\u201315.","journal-title":"J Biol Chem"},{"key":"419_CR137","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","volume":"86","author":"F Chiti","year":"2017","unstructured":"Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem. 2017;86:27\u201368.","journal-title":"Annu Rev Biochem"},{"key":"419_CR138","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41580-018-0060-8","volume":"19","author":"MG Iadanza","year":"2018","unstructured":"Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE. A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol. 2018;19:755\u201373.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"419_CR139","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/jnc.14806","volume":"150","author":"M Delenclos","year":"2019","unstructured":"Delenclos M, Burgess JD, Lamprokostopoulou A, Outeiro TF, Vekrellis K, McLean PJ. Cellular models of alpha-synuclein toxicity and aggregation. J Neurochem. 2019;150:566\u201376.","journal-title":"J Neurochem"},{"key":"419_CR140","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s12031-018-1111-5","volume":"65","author":"SK Sonawane","year":"2018","unstructured":"Sonawane SK, Chinnathambi S. Prion-like propagation of post-translationally modified tau in Alzheimer\u2019s disease: a hypothesis. J Mol Neurosci MN. 2018;65:480\u201390.","journal-title":"J Mol Neurosci MN."},{"key":"419_CR141","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fnmol.2019.00107","volume":"12","author":"E Vasili","year":"2019","unstructured":"Vasili E, Dominguez-Meijide A, Outeiro TF. Spreading of alpha-synuclein and tau: a systematic comparison of the mechanisms involved. Front Mol Neurosci. 2019;12:107.","journal-title":"Front Mol Neurosci."},{"key":"419_CR142","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/ph11020044","volume":"11","author":"F Dur\u00e3es","year":"2018","unstructured":"Dur\u00e3es F, Pinto M, Sousa E. Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals (Basel). 2018;11:44.","journal-title":"Pharmaceuticals (Basel)."},{"key":"419_CR143","doi-asserted-by":"crossref","first-page":"a007500","DOI":"10.1101\/cshperspect.a007500","volume":"3","author":"DA Bosco","year":"2011","unstructured":"Bosco DA, LaVoie MJ, Petsko GA, Ringe D. Proteostasis and movement disorders: Parkinson\u2019s disease and amyotrophic lateral sclerosis. Cold Spring Harb Perspect Biol. 2011;3:a007500.","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"419_CR144","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ymthe.2004.08.019","volume":"10","author":"C Zhou","year":"2004","unstructured":"Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther. 2004;10:1023\u201331.","journal-title":"Mol Ther"},{"key":"419_CR145","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jmb.2007.11.096","volume":"377","author":"SM Lynch","year":"2008","unstructured":"Lynch SM, Zhou C, Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol. 2008;377:136\u201347.","journal-title":"J Mol Biol"},{"key":"419_CR146","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neulet.2009.04.046","volume":"459","author":"B Yuan","year":"2009","unstructured":"Yuan B, Sierks MR. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neurosci Lett. 2009;459:16\u20138.","journal-title":"Neurosci Lett"},{"key":"419_CR147","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4161\/mabs.21696","volume":"4","author":"SN Joshi","year":"2012","unstructured":"Joshi SN, Butler DC, Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. mAbs. 2012;4:686\u201393.","journal-title":"mAbs."},{"key":"419_CR148","doi-asserted-by":"crossref","first-page":"e0165964","DOI":"10.1371\/journal.pone.0165964","volume":"11","author":"DC Butler","year":"2016","unstructured":"Butler DC, Joshi SN, Genst ED, Baghel AS, Dobson CM, Messer A. Bifunctional anti-non-amyloid component alpha-synuclein nanobodies are protective in situ. PLoS One. 2016;11:e0165964.","journal-title":"PLoS One"},{"key":"419_CR149","doi-asserted-by":"crossref","first-page":"6028","DOI":"10.2174\/1381612820666140314121444","volume":"20","author":"A Cardinale","year":"2014","unstructured":"Cardinale A, Merlo D, Giunchedi P, Biocca S. Therapeutic application of intrabodies against age-related neurodegenerative disorders. Curr Pharm Des. 2014;20:6028\u201336.","journal-title":"Curr Pharm Des"},{"key":"419_CR150","first-page":"89","volume":"27","author":"G Meli","year":"2013","unstructured":"Meli G, Krako N, Manca A, Lecci A, Cattaneo A. Intrabodies for protein interference in Alzheimers disease. J Biol Regul Homeost Agents. 2013;27:89\u2013105.","journal-title":"J Biol Regul Homeost Agents"},{"key":"419_CR151","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1471-4159.2006.03989.x","volume":"97","author":"CL Masters","year":"2006","unstructured":"Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer\u2019s disease: implications for neuroimaging and therapeutics. J Neurochem. 2006;97:1700\u201325.","journal-title":"J Neurochem"},{"key":"419_CR152","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1083\/jcb.200410047","volume":"168","author":"P Paganetti","year":"2005","unstructured":"Paganetti P, Calanca V, Galli C, Stefani M, Molinari M. beta-site specific intrabodies to decrease and prevent generation of Alzheimer\u2019s Abeta peptide. J Cell Biol. 2005;168:863\u20138.","journal-title":"J Cell Biol"},{"key":"419_CR153","doi-asserted-by":"crossref","first-page":"27838","DOI":"10.1074\/jbc.M109.055061","volume":"284","author":"I Hayashi","year":"2009","unstructured":"Hayashi I, Takatori S, Urano Y, Iwanari H, Isoo N, Osawa S, et al. Single chain variable fragment against nicastrin inhibits the gamma-secretase activity. J Biol Chem. 2009;284:27838\u201347.","journal-title":"J Biol Chem"},{"key":"419_CR154","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1038\/ncomms4867","volume":"5","author":"G Meli","year":"2014","unstructured":"Meli G, Lecci A, Manca A, Krako N, Albertini V, Benussi L, et al. Conformational targeting of intracellular Abeta oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. Nat Commun. 2014;5:3867.","journal-title":"Nat Commun."},{"key":"419_CR155","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/mt.2009.174","volume":"17","author":"KL Sudol","year":"2009","unstructured":"Sudol KL, Mastrangelo MA, Narrow WC, Frazer ME, Levites YR, Golde TE, et al. Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer\u2019s disease. Mol Ther. 2009;17:2031\u201340.","journal-title":"Mol Ther"},{"key":"419_CR156","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2353\/ajpath.2010.100087","volume":"177","author":"MK Desai","year":"2010","unstructured":"Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ. Early oligodendrocyte\/myelin pathology in Alzheimer\u2019s disease mice constitutes a novel therapeutic target. Am J Pathol. 2010;177:1422\u201335.","journal-title":"Am J Pathol"},{"issue":"658\u2013665","key":"419_CR157","first-page":"e4","volume":"27","author":"SG Cook","year":"2019","unstructured":"Cook SG, Goodell DJ, Restrepo S, Arnold DB, Bayer KU. Simultaneous live imaging of multiple endogenous proteins reveals a mechanism for Alzheimer\u2019s-related plasticity impairment. Cell Rep. 2019;27(658\u2013665):e4.","journal-title":"Cell Rep."},{"key":"419_CR158","doi-asserted-by":"crossref","first-page":"e48750","DOI":"10.7554\/eLife.48750","volume":"8","author":"J-X Dong","year":"2019","unstructured":"Dong J-X, Lee Y, Kirmiz M, Palacio S, Dumitras C, Moreno CM, et al. A toolbox of nanobodies developed and validated for use as intrabodies and nanoscale immunolabels in mammalian brain neurons. eLife. 2019;8:e48750.","journal-title":"eLife."},{"key":"419_CR159","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrneurol.2016.5","volume":"12","author":"JC Rojas","year":"2016","unstructured":"Rojas JC, Boxer AL. Targeting tauopathies for therapeutic translation. Nat Rev Neurol. 2016;12:74\u20136.","journal-title":"Nat Rev Neurol."},{"key":"419_CR160","doi-asserted-by":"crossref","first-page":"104619","DOI":"10.1016\/j.nbd.2019.104619","volume":"134","author":"A Messer","year":"2020","unstructured":"Messer A, Butler DC. Optimizing intracellular antibodies (intrabodies\/nanobodies) to treat neurodegenerative disorders. Neurobiol Dis. 2020;134:104619.","journal-title":"Neurobiol Dis"},{"key":"419_CR161","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jmb.2007.09.053","volume":"374","author":"T Melchionna","year":"2007","unstructured":"Melchionna T, Cattaneo A. A protein silencing switch by ligand-induced proteasome-targeting intrabodies. J Mol Biol. 2007;374:641\u201354.","journal-title":"J Mol Biol"},{"key":"419_CR162","doi-asserted-by":"publisher","DOI":"10.1101\/041756","author":"C Di Primio","year":"2016","unstructured":"Di Primio C, Quercioli V, Siano G, Kovacech B, Novak M, Cattaneo A. Conformational dynamics of Tau in the cell quantified by an intramolecular FRET biosensor in physiological and pathological context. bioRxiv. 2016. https:\/\/doi.org\/10.1101\/041756.","journal-title":"bioRxiv"},{"key":"419_CR163","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13024-019-0340-6","volume":"14","author":"G Gallardo","year":"2019","unstructured":"Gallardo G, Wong CH, Ricardez SM, Mann CN, Lin KH, Leyns CEG, et al. Targeting tauopathy with engineered tau-degrading intrabodies. Mol Neurodegener. 2019;14:38.","journal-title":"Mol Neurodegener."},{"key":"419_CR164","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1074\/jbc.M115.641902","volume":"291","author":"C Liu","year":"2016","unstructured":"Liu C, Song X, Nisbet R, Gotz J. Co-immunoprecipitation with tau isoform-specific antibodies reveals distinct protein interactions and highlights a putative role for 2\u00a0N tau in disease. J Biol Chem. 2016;291:8173\u201388.","journal-title":"J Biol Chem"},{"key":"419_CR165","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awx052","volume":"140","author":"RM Nisbet","year":"2017","unstructured":"Nisbet RM, Van der Jeugd A, Leinenga G, Evans HT, Janowicz PW, Gotz J. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain J Neurol. 2017;140:1220\u201330.","journal-title":"Brain J Neurol."},{"key":"419_CR166","doi-asserted-by":"crossref","first-page":"a024240","DOI":"10.1101\/cshperspect.a024240","volume":"7","author":"M Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. 2017;7:a024240.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"419_CR167","doi-asserted-by":"crossref","first-page":"a024257","DOI":"10.1101\/cshperspect.a024257","volume":"8","author":"MMP Pearce","year":"2018","unstructured":"Pearce MMP, Kopito RR. Prion-like characteristics of polyglutamine-containing proteins. Cold Spring Harb Perspect Med. 2018;8:a024257.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"419_CR168","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41380-018-0021-9","volume":"24","author":"HL Denis","year":"2019","unstructured":"Denis HL, Lauruol F, Cicchetti F. Are immunotherapies for Huntington\u2019s disease a realistic option? Mol Psychiatry. 2019;24:364\u201377.","journal-title":"Mol Psychiatry."},{"key":"419_CR169","doi-asserted-by":"crossref","first-page":"104569","DOI":"10.1016\/j.nbd.2019.104569","volume":"132","author":"HL Denis","year":"2019","unstructured":"Denis HL, David LS, Cicchetti F. Antibody-based therapies for Huntington\u2019s disease: current status and future directions. Neurobiol Dis. 2019;132:104569.","journal-title":"Neurobiol Dis"},{"key":"419_CR170","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nbd.2010.04.007","volume":"40","author":"SF Bortvedt","year":"2010","unstructured":"Bortvedt SF, McLear JA, Messer A, Ahern-Rindell AJ, Wolfgang WJ. Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington\u2019s disease. Neurobiol Dis. 2010;40:130\u20134.","journal-title":"Neurobiol Dis"},{"key":"419_CR171","doi-asserted-by":"crossref","first-page":"17616","DOI":"10.1073\/pnas.0408134101","volume":"101","author":"DW Colby","year":"2004","unstructured":"Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM, et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci USA. 2004;101:17616\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR172","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","volume":"28","author":"AL Southwell","year":"2008","unstructured":"Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, Patterson PH. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci. 2008;28:9013\u201320.","journal-title":"J Neurosci"},{"key":"419_CR173","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","volume":"29","author":"AL Southwell","year":"2009","unstructured":"Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease. J Neurosci. 2009;29:13589\u2013602.","journal-title":"J Neurosci"},{"key":"419_CR174","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","volume":"69","author":"A Snyder-Keller","year":"2010","unstructured":"Snyder-Keller A, McLear JA, Hathorn T, Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice. J Neuropathol Exp Neurol. 2010;69:1078\u201385.","journal-title":"J Neuropathol Exp Neurol."},{"key":"419_CR175","first-page":"7120753","volume":"2016","author":"IA Amaro","year":"2016","unstructured":"Amaro IA, Henderson LA. An intrabody drug (rAAV6-INT41) reduces the binding of N-terminal Huntingtin fragment(s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6\/2 animal model. J Neurodegener Dis. 2016;2016:7120753.","journal-title":"J Neurodegener Dis."},{"key":"419_CR176","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primer. 2017;3:17071.","journal-title":"Nat Rev Dis Primer."},{"key":"419_CR177","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1007\/s12035-017-0856-0","volume":"55","author":"C Maurel","year":"2018","unstructured":"Maurel C, Dangoumau A, Marouillat S, Brulard C, Chami A, Hergesheimer R, et al. Causative genes in amyotrophic lateral sclerosis and protein degradation pathways: a link to neurodegeneration. Mol Neurobiol. 2018;55:6480\u201399.","journal-title":"Mol Neurobiol"},{"key":"419_CR178","first-page":"49","volume":"6","author":"AA Alsultan","year":"2016","unstructured":"Alsultan AA, Waller R, Heath PR, Kirby J. The genetics of amyotrophic lateral sclerosis: current insights. Degener Neurol Neuromuscul Dis. 2016;6:49\u201364.","journal-title":"Degener Neurol Neuromuscul Dis."},{"key":"419_CR179","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/jmg.2010.077180","volume":"47","author":"S Millecamps","year":"2010","unstructured":"Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, Camuzat A, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet. 2010;47:554\u201360.","journal-title":"J Med Genet"},{"key":"419_CR180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59\u201362.","journal-title":"Nature"},{"key":"419_CR181","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nbd.2018.08.021","volume":"121","author":"GD Ghadge","year":"2019","unstructured":"Ghadge GD, Kay BK, Drigotas C, Roos RP. Single chain variable fragment antibodies directed against SOD1 ameliorate disease in mutant SOD1 transgenic mice. Neurobiol Dis. 2019;121:131\u20137.","journal-title":"Neurobiol Dis"},{"key":"419_CR182","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/mt.2013.239","volume":"22","author":"P Patel","year":"2014","unstructured":"Patel P, Kriz J, Gravel M, Soucy G, Bareil C, Gravel C, et al. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther. 2014;22:498\u2013510.","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"419_CR183","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jnc.13588","volume":"138","author":"IRA Mackenzie","year":"2016","unstructured":"Mackenzie IRA, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem. 2016;138(Suppl 1):54\u201370.","journal-title":"J Neurochem"},{"key":"419_CR184","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI123931","volume":"129","author":"S Pozzi","year":"2019","unstructured":"Pozzi S, Thammisetty SS, Codron P, Rahimian R, Plourde KV, Soucy G, et al. Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. J Clin Investig. 2019;129:1581\u201395.","journal-title":"J Clin Investig."},{"key":"419_CR185","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/hmg\/ddp101","volume":"18","author":"A Chartier","year":"2009","unstructured":"Chartier A, Raz V, Sterrenburg E, Verrips CT, van der Maarel SM, Simonelig M. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum Mol Genet. 2009;18:1849\u201359.","journal-title":"Hum Mol Genet"},{"key":"419_CR186","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1096\/fj.06-6306fje","volume":"20","author":"D Gueorguieva","year":"2006","unstructured":"Gueorguieva D, Li S, Walsh N, Mukerji A, Tanha J, Pandey S. Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis. FASEB J. 2006;20:2636\u20138.","journal-title":"FASEB J."},{"key":"419_CR187","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1073\/pnas.92.8.3137","volume":"92","author":"JH Richardson","year":"1995","unstructured":"Richardson JH, Sodroski JG, Waldmann TA, Marasco WA. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci USA. 1995;92:3137\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR188","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.gt.3300644","volume":"5","author":"JH Richardson","year":"1998","unstructured":"Richardson JH, Hofmann W, Sodroski JG, Marasco WA. Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene Ther. 1998;5:635\u201344.","journal-title":"Gene Ther"},{"key":"419_CR189","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1073\/pnas.97.2.805","volume":"97","author":"P Steinberger","year":"2000","unstructured":"Steinberger P, Andris-Widhopf J, Buhler B, Torbett BE, Barbas CF 3rd. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci USA. 2000;97:805\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR190","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/sj.gt.3301411","volume":"8","author":"M BouHamdan","year":"2001","unstructured":"BouHamdan M, Strayer DS, Wei D, Mukhtar M, Duan LX, Hoxie J, et al. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther. 2001;8:408\u201318.","journal-title":"Gene Ther"},{"key":"419_CR191","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.gt.3302329","volume":"11","author":"P Cordelier","year":"2004","unstructured":"Cordelier P, Kulkowsky JW, Ko C, Matskevitch AA, McKee HJ, Rossi JJ, et al. Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther. 2004;11:1627\u201337.","journal-title":"Gene Ther"},{"key":"419_CR192","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molbrainres.2004.11.015","volume":"135","author":"M Mukhtar","year":"2005","unstructured":"Mukhtar M, Acheampong E, Khan MA, Bouhamdan M, Pomerantz RJ. Down-modulation of the CXCR4 co-receptor by intracellular expression of a single chain variable fragment (SFv) inhibits HIV-1 entry into primary human brain microvascular endothelial cells and post-mitotic neurons. Brain Res Mol Brain Res. 2005;135:48\u201357.","journal-title":"Brain Res Mol Brain Res"},{"key":"419_CR193","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/sj.gt.3302801","volume":"13","author":"CH Swan","year":"2006","unstructured":"Swan CH, Buhler B, Steinberger P, Tschan MP, Barbas CF 3rd, Torbett BE. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther. 2006;13:1480\u201392.","journal-title":"Gene Ther"},{"key":"419_CR194","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11103-005-4091-0","volume":"58","author":"ME Villani","year":"2005","unstructured":"Villani ME, Roggero P, Bitti O, Benvenuto E, Franconi R. Immunomodulation of cucumber mosaic virus infection by intrabodies selected in vitro from a stable single-framework phage display library. Plant Mol Biol. 2005;58:305\u201316.","journal-title":"Plant Mol Biol"},{"key":"419_CR195","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1364-3703.2011.00752.x","volume":"12","author":"K-BG Scholthof","year":"2011","unstructured":"Scholthof K-BG, Adkins S, Czosnek H, Palukaitis P, Jacquot E, Hohn T, et al. Top 10 plant viruses in molecular plant pathology. Mol Plant Pathol. 2011;12:938\u201354.","journal-title":"Mol Plant Pathol."},{"key":"419_CR196","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.phytochem.2019.03.006","volume":"162","author":"S Matic","year":"2019","unstructured":"Matic S, Noris E, Contin R, Marian D, Thompson J. Engineering partial resistance to cucumber mosaic virus in tobacco using intrabodies specific for the viral polymerase. Phytochemistry. 2019;162:99\u2013108.","journal-title":"Phytochemistry"},{"key":"419_CR197","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11103-015-0282-5","volume":"87","author":"A Ghannam","year":"2015","unstructured":"Ghannam A, Kumari S, Muyldermans S, Abbady AQ. Camelid nanobodies with high affinity for broad bean mottle virus: a possible promising tool to immunomodulate plant resistance against viruses. Plant Mol Biol. 2015;87:355\u201369.","journal-title":"Plant Mol Biol"},{"key":"419_CR198","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/pbi.12819","volume":"16","author":"C Hemmer","year":"2018","unstructured":"Hemmer C, Djennane S, Ackerer L, Hleibieh K, Marmonier A, Gersch S, et al. Nanobody-mediated resistance to Grapevine fanleaf virus in plants. Plant Biotechnol J. 2018;16:660\u201371.","journal-title":"Plant Biotechnol J"},{"key":"419_CR199","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1099\/vir.0.80075-0","volume":"85","author":"F Vascotto","year":"2004","unstructured":"Vascotto F, Campagna M, Visintin M, Cattaneo A, Burrone OR. Effects of intrabodies specific for rotavirus NSP5 during the virus replicative cycle. J Gen Virol. 2004;85:3285\u201390.","journal-title":"J Gen Virol"},{"key":"419_CR200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.virusres.2014.06.016","volume":"190","author":"U Desselberger","year":"2014","unstructured":"Desselberger U. Rotaviruses. Virus Res. 2014;190:75\u201396.","journal-title":"Virus Res"},{"issue":"Suppl 4","key":"419_CR201","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","volume":"26","author":"NM Bouvier","year":"2008","unstructured":"Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008;26(Suppl 4):D49\u201353.","journal-title":"Vaccine."},{"key":"419_CR202","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1128\/JVI.02693-14","volume":"89","author":"J Ashour","year":"2015","unstructured":"Ashour J, Schmidt FI, Hanke L, Cragnolini J, Cavallari M, Altenburg A, et al. Intracellular expression of camelid single-domain antibodies specific for influenza virus nucleoprotein uncovers distinct features of its nuclear localization. J Virol. 2015;89:2792\u2013800.","journal-title":"J Virol"},{"key":"419_CR203","doi-asserted-by":"crossref","first-page":"e01046-18","DOI":"10.1128\/JVI.01046-18","volume":"93","author":"J Tome-Amat","year":"2019","unstructured":"Tome-Amat J, Ramos I, Amanor F, Fernandez-Sesma A, Ashour J. Influenza a virus utilizes low-affinity, high-avidity interactions with the nuclear import machinery to ensure infection and immune evasion. J Virol. 2019;93:e01046-18.","journal-title":"J Virol"},{"key":"419_CR204","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1099\/0022-1317-19-1-51","volume":"19","author":"JS Mackenzie","year":"1973","unstructured":"Mackenzie JS, Dimmock NJ. A preliminary study of physiological characteristics of temperature-sensitive mutants of influenza virus. J Gen Virol. 1973;19:51\u201363.","journal-title":"J Gen Virol"},{"key":"419_CR205","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1073\/pnas.0914994107","volume":"107","author":"B Manicassamy","year":"2010","unstructured":"Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, Garcia-Sastre A. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci USA. 2010;107:11531\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR206","doi-asserted-by":"crossref","first-page":"e0121491","DOI":"10.1371\/journal.pone.0121491","volume":"10","author":"S De Baets","year":"2015","unstructured":"De Baets S, Verhelst J, Van den Hoecke S, Smet A, Schotsaert M, Job ER, et al. A GFP expressing influenza A virus to report in vivo tropism and protection by a matrix protein 2 ectodomain-specific monoclonal antibody. PLoS One. 2015;10:e0121491.","journal-title":"PLoS One"},{"key":"419_CR207","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s001140050562","volume":"86","author":"B Beer","year":"1999","unstructured":"Beer B, Kurth R, Bukreyev A. Characteristics of Filoviridae: marburg and Ebola viruses. Naturwissenschaften. 1999;86:8\u201317.","journal-title":"Naturwissenschaften"},{"key":"419_CR208","doi-asserted-by":"crossref","first-page":"1178122X1984992","DOI":"10.1177\/1178122X19849927","volume":"10","author":"S Languon","year":"2019","unstructured":"Languon S, Quaye O. Filovirus disease outbreaks: a chronological overview. Virology (Auck). 2019;10:1178122X19849927.","journal-title":"Virology (Auck)."},{"key":"419_CR209","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3389\/fimmu.2017.01197","volume":"8","author":"TL Darling","year":"2017","unstructured":"Darling TL, Sherwood LJ, Hayhurst A. Intracellular crosslinking of filoviral nucleoproteins with xintrabodies restricts viral packaging. Front Immunol. 2017;8:1197.","journal-title":"Front Immunol."},{"key":"419_CR210","doi-asserted-by":"crossref","first-page":"a006924","DOI":"10.1101\/cshperspect.a006924","volume":"2","author":"WI Sundquist","year":"2012","unstructured":"Sundquist WI, Kr\u00e4usslich H-G. HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med. 2012;2:a006924.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"419_CR211","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/imr.12066","volume":"254","author":"AA Okoye","year":"2013","unstructured":"Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. 2013;254:54\u201364.","journal-title":"Immunol Rev"},{"key":"419_CR212","volume-title":"HIV disease","author":"AA Justiz Vaillant","year":"2019","unstructured":"Justiz Vaillant AA, Gulick PG. HIV disease. Treasure Island: StatPearls Publishing; 2019."},{"key":"419_CR213","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF03401802","volume":"3","author":"R Levin","year":"1997","unstructured":"Levin R, Mhashilkar AM, Dorfman T, Bukovsky A, Zani C, Bagley J, et al. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med. 1997;3:96\u2013110.","journal-title":"Mol Med"},{"key":"419_CR214","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1126\/science.3001934","volume":"231","author":"JS McDougal","year":"1986","unstructured":"McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JK. Binding of HTLV-III\/LAV to T4\u2009+\u2009T cells by a complex of the 110\u00a0K viral protein and the T4 molecule. Science. 1986;231:382\u20135.","journal-title":"Science"},{"key":"419_CR215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/hum.1998.9.4-487","volume":"9","author":"MC Poznansky","year":"1998","unstructured":"Poznansky MC, Foxall R, Mhashilkar A, Coker R, Jones S, Ramstedt U, et al. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum Gene Ther. 1998;9:487\u201396.","journal-title":"Hum Gene Ther"},{"key":"419_CR216","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1128\/JVI.64.12.6314-6318.1990","volume":"64","author":"E Helseth","year":"1990","unstructured":"Helseth E, Olshevsky U, Gabuzda D, Ardman B, Haseltine W, Sodroski J. Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion. J Virol. 1990;64:6314\u20138.","journal-title":"J Virol"},{"issue":"160","key":"419_CR217","first-page":"1489","volume":"1998","author":"P Zhou","year":"1950","unstructured":"Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network. J Immunol Baltim Md. 1950;1998(160):1489\u201396.","journal-title":"J Immunol Baltim Md"},{"key":"419_CR218","doi-asserted-by":"crossref","first-page":"32036","DOI":"10.1074\/jbc.M201906200","volume":"277","author":"J Goncalves","year":"2002","unstructured":"Goncalves J, Silva F, Freitas-Vieira A, Santa-Marta M, Malho R, Yang X, et al. Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J Biol Chem. 2002;277:32036\u201345.","journal-title":"J Biol Chem"},{"key":"419_CR219","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1074\/jbc.M313093200","volume":"279","author":"A Mehle","year":"2004","unstructured":"Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem. 2004;279:7792\u20138.","journal-title":"J Biol Chem"},{"key":"419_CR220","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/338254a0","volume":"338","author":"MH Malim","year":"1989","unstructured":"Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature. 1989;338:254\u20137.","journal-title":"Nature"},{"key":"419_CR221","doi-asserted-by":"crossref","first-page":"21768","DOI":"10.1074\/jbc.M110.112490","volume":"285","author":"T Vercruysse","year":"2010","unstructured":"Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D. An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production. J Biol Chem. 2010;285:21768\u201380.","journal-title":"J Biol Chem"},{"key":"419_CR222","doi-asserted-by":"crossref","first-page":"e113729","DOI":"10.1371\/journal.pone.0113729","volume":"9","author":"J Matz","year":"2014","unstructured":"Matz J, Herate C, Bouchet J, Dusetti N, Gayet O, Baty D, et al. Selection of intracellular single-domain antibodies targeting the HIV-1 Vpr protein by cytoplasmic yeast two-hybrid system. PLoS One. 2014;9:e113729.","journal-title":"PLoS One"},{"key":"419_CR223","doi-asserted-by":"crossref","first-page":"E1310","DOI":"10.3390\/cells8111310","volume":"8","author":"H Fabryova","year":"2019","unstructured":"Fabryova H, Strebel K. Vpr and its cellular interaction partners: R we there yet? Cells. 2019;8:E1310.","journal-title":"Cells"},{"key":"419_CR224","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/j.1460-2075.1995.tb07140.x","volume":"14","author":"AM Mhashilkar","year":"1995","unstructured":"Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 1995;14:1542\u201351.","journal-title":"EMBO J"},{"key":"419_CR225","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1128\/JVI.71.9.6486-6494.1997","volume":"71","author":"AM Mhashilkar","year":"1997","unstructured":"Mhashilkar AM, Biswas DK, LaVecchio J, Pardee AB, Marasco WA. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. J Virol. 1997;71:6486\u201394.","journal-title":"J Virol"},{"key":"419_CR226","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1089\/hum.2011.184","volume":"23","author":"SE Braun","year":"2012","unstructured":"Braun SE, Taube R, Zhu Q, Wong FE, Murakami A, Kamau E, et al. In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat. Hum Gene Ther. 2012;23:917\u201331.","journal-title":"Hum Gene Ther"},{"key":"419_CR227","doi-asserted-by":"crossref","first-page":"16869","DOI":"10.1038\/s41598-017-16742-2","volume":"7","author":"L Bao","year":"2017","unstructured":"Bao L, Hannon C, Cruz-Mignoni A, Ptchelkine D, Sun M-Y, Miller A, et al. Intracellular immunization against HIV infection with an intracellular antibody that mimics HIV integrase binding to the cellular LEDGF protein. Sci Rep. 2017;7:16869.","journal-title":"Sci Rep."},{"key":"419_CR228","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","volume":"27","author":"B Chen","year":"2019","unstructured":"Chen B. Molecular mechanism of HIV-1 entry. Trends Microbiol. 2019;27:878\u201391.","journal-title":"Trends Microbiol"},{"key":"419_CR229","doi-asserted-by":"crossref","first-page":"e50026","DOI":"10.1371\/journal.pone.0050026","volume":"7","author":"J Helma","year":"2012","unstructured":"Helma J, Schmidthals K, Lux V, Nuske S, Scholz AM, Krausslich H-G, et al. Direct and dynamic detection of HIV-1 in living cells. PLoS One. 2012;7:e50026.","journal-title":"PLoS One"},{"key":"419_CR230","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1128\/JVI.02634-14","volume":"89","author":"A Casini","year":"2015","unstructured":"Casini A, Olivieri M, Vecchi L, Burrone OR, Cereseto A. Reduction of HIV-1 infectivity through endoplasmic reticulum-associated degradation-mediated Env depletion. J Virol. 2015;89:2966\u201371.","journal-title":"J Virol"},{"key":"419_CR231","first-page":"289","volume":"115","author":"DD Richman","year":"2004","unstructured":"Richman DD, Little SJ, Smith DM, Wrin T, Petropoulos C, Wong JK. HIV evolution and escape. Trans Am Clin Climatol Assoc. 2004;115:289\u2013303.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"419_CR232","first-page":"4098","volume":"23","author":"AP Rice","year":"2017","unstructured":"Rice AP. The HIV-1 Tat protein: mechanism of action and target for HIV-1 cure strategies. Curr Pharm Des. 2017;23:4098\u2013102.","journal-title":"Curr Pharm Des"},{"key":"419_CR233","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00001622-199903000-00004","volume":"11","author":"LK Aguilar","year":"1999","unstructured":"Aguilar LK, Rooney CM, Heslop HE. Lymphoproliferative disorders involving Epstein\u2013Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol. 1999;11:96\u2013101.","journal-title":"Curr Opin Oncol"},{"key":"419_CR234","doi-asserted-by":"crossref","first-page":"20160266","DOI":"10.1098\/rstb.2016.0266","volume":"372","author":"RM Lunn","year":"2017","unstructured":"Lunn RM, Jahnke GD, Rabkin CS. Tumour virus epidemiology. Philos Trans R Soc Lond B Biol Sci. 2017;372:20160266.","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"419_CR235","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/sj.gt.3300706","volume":"5","author":"A Piche","year":"1998","unstructured":"Piche A, Kasono K, Johanning F, Curiel TJ, Curiel DT. Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody. Gene Ther. 1998;5:1171\u20139.","journal-title":"Gene Ther"},{"key":"419_CR236","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jmb.2003.09.073","volume":"335","author":"F Gennari","year":"2004","unstructured":"Gennari F, Mehta S, Wang Y, St Clair Tallarico A, Palu G, Marasco WA. Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. J Mol Biol. 2004;335:193\u2013207.","journal-title":"J Mol Biol."},{"key":"419_CR237","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.284.5414.641","volume":"284","author":"ME Ballestas","year":"1999","unstructured":"Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science. 1999;284:641\u20134.","journal-title":"Science"},{"key":"419_CR238","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1182\/blood-2005-04-1627","volume":"106","author":"S Corte-Real","year":"2005","unstructured":"Corte-Real S, Collins C, da Silva FA, Simas JP, Barbas CF III, Chang Y, et al. Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells. Blood. 2005;106:3797\u2013802.","journal-title":"Blood."},{"key":"419_CR239","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1128\/JVI.75.7.3325-3334.2001","volume":"75","author":"H Li","year":"2001","unstructured":"Li H, Wang H, Nicholas J. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling. J Virol. 2001;75:3325\u201334.","journal-title":"J Virol"},{"key":"419_CR240","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ejcb.2010.10.016","volume":"90","author":"J Suthaus","year":"2011","unstructured":"Suthaus J, Adam N, Grotzinger J, Scheller J, Rose-John S. Viral interleukin-6: structure, pathophysiology and strategies of neutralization. Eur J Cell Biol. 2011;90:495\u2013504.","journal-title":"Eur J Cell Biol"},{"key":"419_CR241","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1128\/JVI.00420-06","volume":"80","author":"M Kovaleva","year":"2006","unstructured":"Kovaleva M, Bussmeyer I, Rabe B, Grotzinger J, Sudarman E, Eichler J, et al. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol. 2006;80:8510\u201320.","journal-title":"J Virol"},{"key":"419_CR242","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","volume":"146","author":"DM Harper","year":"2017","unstructured":"Harper DM, DeMars LR. HPV vaccines\u2014a review of the first decade. Gynecol Oncol. 2017;146:196\u2013204.","journal-title":"Gynecol Oncol"},{"key":"419_CR243","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mrrev.2016.07.002","volume":"772","author":"ME Harden","year":"2017","unstructured":"Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3\u201312.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"419_CR244","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.virol.2013.04.013","volume":"445","author":"A Roman","year":"2013","unstructured":"Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013;445:138\u201368.","journal-title":"Virology"},{"key":"419_CR245","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.virol.2013.04.026","volume":"445","author":"SB Vande Pol","year":"2013","unstructured":"Vande Pol SB, Klingelhutz AJ. Papillomavirus E6 oncoproteins. Virology. 2013;445:115\u201337.","journal-title":"Virology"},{"key":"419_CR246","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ijc.21052","volume":"116","author":"L Accardi","year":"2005","unstructured":"Accardi L, Dona MG, Di Bonito P, Giorgi C. Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells. Int J Cancer. 2005;116:564\u201370.","journal-title":"Int J Cancer"},{"key":"419_CR247","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-11-17","volume":"11","author":"L Accardi","year":"2011","unstructured":"Accardi L, Don\u00e0 MG, Mileo AM, Paggi MG, Federico A, Torreri P, et al. Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV 16-positive cells. BMC Cancer. 2011;11:17.","journal-title":"BMC Cancer."},{"key":"419_CR248","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1002\/ijc.28604","volume":"134","author":"L Accardi","year":"2014","unstructured":"Accardi L, Paolini F, Mandarino A, Percario Z, Di Bonito P, Di Carlo V, et al. In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. Int J Cancer. 2014;134:2742\u20137.","journal-title":"Int J Cancer"},{"key":"419_CR249","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jmb.2005.10.077","volume":"355","author":"H Griffin","year":"2006","unstructured":"Griffin H, Elston R, Jackson D, Ansell K, Coleman M, Winter G, et al. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol. 2006;355:360\u201378.","journal-title":"J Mol Biol"},{"key":"419_CR250","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.18632\/oncotarget.6925","volume":"7","author":"C Amici","year":"2016","unstructured":"Amici C, Visintin M, Verachi F, Paolini F, Percario Z, Di Bonito P, et al. A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models. Oncotarget. 2016;7:15539\u201353.","journal-title":"Oncotarget."},{"key":"419_CR251","doi-asserted-by":"crossref","first-page":"12680","DOI":"10.1038\/s41598-019-49061-9","volume":"9","author":"A Steels","year":"2019","unstructured":"Steels A, Vannevel L, Zwaenepoel O, Gettemans J. Nb-induced stabilisation of p53 in HPV-infected cells. Sci Rep. 2019;9:12680.","journal-title":"Sci Rep."},{"key":"419_CR252","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-virology-110615-042238","volume":"3","author":"B Venkatakrishnan","year":"2016","unstructured":"Venkatakrishnan B, Zlotnick A. The structural biology of hepatitis B virus: form and function. Annu Rev Virol. 2016;3:429\u201351.","journal-title":"Annu Rev Virol."},{"key":"419_CR253","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4254\/wjh.v7.i24.2503","volume":"7","author":"S Walayat","year":"2015","unstructured":"Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, Dhillon S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol. 2015;7:2503\u20139.","journal-title":"World J Hepatol."},{"key":"419_CR254","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0264-410X(99)00389-8","volume":"18","author":"D Rey","year":"2000","unstructured":"Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine. 2000;18:1161\u20135.","journal-title":"Vaccine."},{"key":"419_CR255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1278976","volume":"13","author":"F-X Catherine","year":"2017","unstructured":"Catherine F-X, Piroth L. Hepatitis B virus vaccination in HIV-infected people: a review. Hum Vaccines Immunother. 2017;13:1\u201310.","journal-title":"Hum Vaccines Immunother."},{"key":"419_CR256","doi-asserted-by":"crossref","first-page":"a021410","DOI":"10.1101\/cshperspect.a021410","volume":"5","author":"JH MacLachlan","year":"2015","unstructured":"MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5:a021410.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"419_CR257","doi-asserted-by":"crossref","first-page":"11941","DOI":"10.3748\/wjg.v21.i42.11941","volume":"21","author":"R Zampino","year":"2015","unstructured":"Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol. 2015;21:11941\u201353.","journal-title":"World J Gastroenterol"},{"key":"419_CR258","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97\u2013107.","journal-title":"J Viral Hepat."},{"key":"419_CR259","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.22609","volume":"49","author":"B Serruys","year":"2009","unstructured":"Serruys B, Van Houtte F, Verbrugghe P, Leroux-Roels G, Vanlandschoot P. Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice. Hepatology. 2009;49:39\u201349.","journal-title":"Hepatology"},{"key":"419_CR260","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1099\/vir.0.016063-0","volume":"91","author":"B Serruys","year":"2010","unstructured":"Serruys B, Van Houtte F, Farhoudi-Moghadam A, Leroux-Roels G, Vanlandschoot P. Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies. J Gen Virol. 2010;91:643\u201352.","journal-title":"J Gen Virol"},{"key":"419_CR261","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.virol.2010.12.034","volume":"411","author":"R Walsh","year":"2011","unstructured":"Walsh R, Nuttall S, Revill P, Colledge D, Cabuang L, Soppe S, et al. Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virology. 2011;411:132\u201341.","journal-title":"Virology"},{"key":"419_CR262","volume-title":"Global hepatitis report, 2017","author":"WHO","year":"2017","unstructured":"WHO. Global hepatitis report, 2017. Geneva: WHO; 2017."},{"key":"419_CR263","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41435-019-0066-z","volume":"20","author":"S Pol","year":"2019","unstructured":"Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun. 2019;20:436\u201346.","journal-title":"Genes Immun"},{"key":"419_CR264","first-page":"113","volume":"369","author":"D Moradpour","year":"2013","unstructured":"Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol. 2013;369:113\u201342.","journal-title":"Curr Top Microbiol Immunol"},{"key":"419_CR265","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/bbrc.1999.1350","volume":"263","author":"T Heintges","year":"1999","unstructured":"Heintges T, zu Putlitz J, Wands JR. Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein. Biochem Biophys Res Commun. 1999;263:410\u20138.","journal-title":"Biochem Biophys Res Commun."},{"key":"419_CR266","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/hep.22366","volume":"48","author":"J Karthe","year":"2008","unstructured":"Karthe J, Tessmann K, Li J, Machida R, Daleman M, Haussinger D, et al. Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin. Hepatology. 2008;48:702\u201312.","journal-title":"Hepatology"},{"key":"419_CR267","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jgv.0.000423","volume":"97","author":"R Suzuki","year":"2016","unstructured":"Suzuki R, Saito K, Matsuda M, Sato M, Kanegae Y, Shi G, et al. Single-domain intrabodies against hepatitis C virus core inhibit viral propagation and core-induced NFkappaB activation. J Gen Virol. 2016;97:887\u201392.","journal-title":"J Gen Virol"},{"key":"419_CR268","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","volume":"55","author":"P Halfon","year":"2011","unstructured":"Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55:192\u2013206.","journal-title":"J Hepatol"},{"key":"419_CR269","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-8976-8_1","volume":"1911","author":"DK Li","year":"2019","unstructured":"Li DK, Chung RT. Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus. Methods Mol Biol. 2019;1911:3\u201332.","journal-title":"Methods Mol Biol"},{"key":"419_CR270","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2010.08.001","volume":"88","author":"M Gal-Tanamy","year":"2010","unstructured":"Gal-Tanamy M, Zemel R, Bachmatov L, Jangra RK, Shapira A, Villanueva RA, et al. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies. Antiviral Res. 2010;88:95\u2013106.","journal-title":"Antiviral Res"},{"key":"419_CR271","first-page":"3081","volume":"6","author":"RD Alvarez","year":"2000","unstructured":"Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2000;6:3081\u20137.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"419_CR272","first-page":"239","volume":"10","author":"UH Weidle","year":"2013","unstructured":"Weidle UH, Maisel D, Brinkmann U, Tiefenthaler G. The translational potential for target validation and therapy using intracellular antibodies in oncology. Cancer Genom Proteom. 2013;10:239\u201350.","journal-title":"Cancer Genom Proteom"},{"key":"419_CR273","doi-asserted-by":"crossref","first-page":"e0151041","DOI":"10.1371\/journal.pone.0151041","volume":"11","author":"A Buchfellner","year":"2016","unstructured":"Buchfellner A, Yurlova L, Nuske S, Scholz AM, Bogner J, Ruf B, et al. A new nanobody-based biosensor to study endogenous PARP1 in vitro and in live human cells. PLoS One. 2016;11:e0151041.","journal-title":"PLoS One"},{"key":"419_CR274","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/0008-5472.CAN-04-4292","volume":"65","author":"Y Liu","year":"2005","unstructured":"Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, et al. Inhibition of HER-2\/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 2005;65:3404\u20139.","journal-title":"Cancer Res"},{"key":"419_CR275","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1038\/sj.onc.1202576","volume":"17","author":"SA Amundson","year":"1998","unstructured":"Amundson SA, Myers TG, Fornace AJ. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 1998;17:3287\u201399.","journal-title":"Oncogene"},{"key":"419_CR276","doi-asserted-by":"crossref","first-page":"e2004413","DOI":"10.1371\/journal.pbio.2004413","volume":"17","author":"T Liu","year":"2019","unstructured":"Liu T, Kuwana T, Zhang H, Vander Heiden MG, Lerner RA, Newmeyer DD. Phenotypic selection with an intrabody library reveals an anti-apoptotic function of PKM2 requiring Mitofusin-1. PLoS Biol. 2019;17:e2004413.","journal-title":"PLoS Biol"},{"key":"419_CR277","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/mi.11.1.4","volume":"11","author":"PA Johnston","year":"2011","unstructured":"Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Mol Interv. 2011;11:18\u201326.","journal-title":"Mol Interv."},{"key":"419_CR278","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1073\/pnas.1316815111","volume":"111","author":"MY Koo","year":"2014","unstructured":"Koo MY, Park J, Lim JM, Joo SY, Shin S-P, Shim HB, et al. Selective inhibition of the function of tyrosine-phosphorylated STAT3 with a phosphorylation site-specific intrabody. Proc Natl Acad Sci USA. 2014;111:6269\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR279","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tcb.2014.12.006","volume":"25","author":"L Seguin","year":"2015","unstructured":"Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25:234\u201340.","journal-title":"Trends Cell Biol"},{"key":"419_CR280","doi-asserted-by":"crossref","first-page":"24835","DOI":"10.1074\/jbc.M203149200","volume":"277","author":"P Koistinen","year":"2002","unstructured":"Koistinen P, Heino J. The selective regulation of alpha Vbeta 1 integrin expression is based on the hierarchical formation of alpha V-containing heterodimers. J Biol Chem. 2002;277:24835\u201341.","journal-title":"J Biol Chem"},{"key":"419_CR281","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7150\/jca.10879","volume":"6","author":"P Thammasit","year":"2015","unstructured":"Thammasit P, Sangboonruang S, Suwanpairoj S, Khamaikawin W, Intasai N, Kasinrerk W, et al. Intracellular acidosis promotes mitochondrial apoptosis pathway: role of EMMPRIN down-regulation via specific single-chain Fv intrabody. J Cancer. 2015;6:276\u201386.","journal-title":"J Cancer."},{"key":"419_CR282","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/cbr.2016.2126","volume":"32","author":"T Panich","year":"2017","unstructured":"Panich T, Tragoolpua K, Pata S, Tayapiwatana C, Intasai N. Downregulation of extracellular matrix metalloproteinase inducer by scFv-M6-1B9 intrabody suppresses cervical cancer invasion through inhibition of urokinase-type plasminogen activator. Cancer Biother Radiopharm. 2017;32:1\u20138.","journal-title":"Cancer Biother Radiopharm."},{"key":"419_CR283","first-page":"2460","volume":"31","author":"L Bertier","year":"2017","unstructured":"Bertier L, Boucherie C, Zwaenepoel O, Vanloo B, Van Troys M, Van Audenhove I, et al. Inhibitory cortactin nanobodies delineate the role of NTA. FASEB J Off Publ Fed Am Soc Exp Biol. 2017;31:2460\u201376.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol."},{"key":"419_CR284","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.biopha.2018.03.064","volume":"102","author":"L Bertier","year":"2018","unstructured":"Bertier L, Hebbrecht T, Mettepenningen E, De Wit N, Zwaenepoel O, Verhelle A, et al. Nanobodies targeting cortactin proline rich, helical and actin binding regions downregulate invadopodium formation and matrix degradation in SCC-61 cancer cells. Biomed Pharmacother Biomed Pharmacother. 2018;102:230\u201341.","journal-title":"Biomed Pharmacother Biomed Pharmacother."},{"key":"419_CR285","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1096\/fj.02-0942fje","volume":"17","author":"YY Wheeler","year":"2003","unstructured":"Wheeler YY, Kute TE, Willingham MC, Chen S-Y, Sane DC. Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J. 2003;17:1733\u20135.","journal-title":"FASEB J."},{"key":"419_CR286","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jim.2005.03.007","volume":"300","author":"T Boldicke","year":"2005","unstructured":"Boldicke T, Weber H, Mueller PP, Barleon B, Bernal M. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2\/KDR). J Immunol Methods. 2005;300:146\u201359.","journal-title":"J Immunol Methods"},{"key":"419_CR287","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1073\/pnas.0503168102","volume":"102","author":"N Jendreyko","year":"2005","unstructured":"Jendreyko N, Popkov M, Rader C, Barbas CF 3rd. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci USA. 2005;102:8293\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR288","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/0008-5472.972.65.3","volume":"65","author":"M Popkov","year":"2005","unstructured":"Popkov M, Jendreyko N, McGavern DB, Rader C, Barbas CF 3rd. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res. 2005;65:972\u201381.","journal-title":"Cancer Res"},{"key":"419_CR289","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","volume":"20","author":"C Viallard","year":"2017","unstructured":"Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20:409\u201326.","journal-title":"Angiogenesis"},{"key":"419_CR290","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93:442\u201359.","journal-title":"Am J Hematol"},{"key":"419_CR291","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s11095-011-0654-8","volume":"29","author":"AS Dixon","year":"2012","unstructured":"Dixon AS, Constance JE, Tanaka T, Rabbitts TH, Lim CS. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs. Pharm Res. 2012;29:1098\u2013109.","journal-title":"Pharm Res"},{"key":"419_CR292","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1042\/BST20180173","volume":"46","author":"SP Mo","year":"2018","unstructured":"Mo SP, Coulson JM, Prior IA. RAS variant signalling. Biochem Soc Trans. 2018;46:1325\u201332.","journal-title":"Biochem Soc Trans"},{"key":"419_CR293","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1006\/bbrc.1993.2496","volume":"197","author":"S Biocca","year":"1993","unstructured":"Biocca S, Pierandrei-Amaldi P, Cattaneo A. Intracellular expression of anti-p21ras single chain Fv fragments inhibits meiotic maturation of xenopus oocytes. Biochem Biophys Res Commun. 1993;197:422\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"419_CR294","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-5793(98)01369-6","volume":"439","author":"A Cardinale","year":"1998","unstructured":"Cardinale A, Lener M, Messina S, Cattaneo A, Biocca S. The mode of action of Y13-259 scFv fragment intracellularly expressed in mammalian cells. FEBS Lett. 1998;439:197\u2013202.","journal-title":"FEBS Lett"},{"key":"419_CR295","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.1038\/s41598-019-44908-7","volume":"9","author":"JS Chambers","year":"2019","unstructured":"Chambers JS, Brend T, Rabbitts TH. Cancer cell killing by target antigen engagement with engineered complementary intracellular antibody single domains fused to pro-caspase3. Sci Rep. 2019;9:8553.","journal-title":"Sci Rep"},{"key":"419_CR296","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1038\/s41467-018-05707-2","volume":"9","author":"CE Quevedo","year":"2018","unstructured":"Quevedo CE, Cruz-Migoni A, Bery N, Miller A, Tanaka T, Petch D, et al. Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment. Nat Commun. 2018;9:3169.","journal-title":"Nat Commun."},{"key":"419_CR297","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","volume":"33","author":"M Mohty","year":"2019","unstructured":"Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019;33:2767\u201378.","journal-title":"Leukemia"},{"key":"419_CR298","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","volume":"8","author":"C Zhang","year":"2017","unstructured":"Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, et al. chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533.","journal-title":"Front Immunol."},{"key":"419_CR299","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"419_CR300","doi-asserted-by":"crossref","first-page":"e30684","DOI":"10.1371\/journal.pone.0030684","volume":"7","author":"C Zhang","year":"2012","unstructured":"Zhang C, Helmsing S, Zagrebelsky M, Schirrmann T, Marschall ALJ, Sch\u00fcngel M, et al. Suppression of p75 neurotrophin receptor surface expression with intrabodies influences Bcl-xL mRNA expression and neurite outgrowth in PC12 cells. PLoS One. 2012;7:e30684.","journal-title":"PLoS One"},{"key":"419_CR301","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1096\/fj.14-267351","volume":"29","author":"A Ordonez","year":"2015","unstructured":"Ordonez A, Perez J, Tan L, Dickens JA, Motamedi-Shad N, Irving JA, et al. A single-chain variable fragment intrabody prevents intracellular polymerization of Z alpha1-antitrypsin while allowing its antiproteinase activity. FASEB J. 2015;29:2667\u201378.","journal-title":"FASEB J."},{"key":"419_CR302","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1515\/hsz-2018-0330","volume":"400","author":"G Bala","year":"2019","unstructured":"Bala G, Crauwels M, Blykers A, Remory I, Marschall ALJ, Dubel S, et al. Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis\u2014impact of radiochemistry on pharmacokinetics. Biol Chem. 2019;400:323\u201332.","journal-title":"Biol Chem"},{"key":"419_CR303","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","volume":"31","author":"CD Godwin","year":"2017","unstructured":"Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31:1855\u201368.","journal-title":"Leukemia"},{"key":"419_CR304","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378:331\u201344.","journal-title":"N Engl J Med"},{"key":"419_CR305","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328.","journal-title":"N Engl J Med"},{"key":"419_CR306","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gokbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474\u201387.","journal-title":"Cancer"},{"key":"419_CR307","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.immuni.2015.04.008","volume":"42","author":"M Zehner","year":"2015","unstructured":"Zehner M, Marschall AL, Bos E, Schloetel J-G, Kreer C, Fehrenschild D, et al. The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells. Immunity. 2015;42:850\u201363.","journal-title":"Immunity"},{"key":"419_CR308","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2174\/156652309788921062","volume":"9","author":"SD Reed","year":"2009","unstructured":"Reed SD, Li S. Electroporation advances in large animals. Curr Gene Ther. 2009;9:316\u201326.","journal-title":"Curr Gene Ther"},{"key":"419_CR309","doi-asserted-by":"crossref","first-page":"e5727","DOI":"10.1371\/journal.pone.0005727","volume":"4","author":"E Kvam","year":"2009","unstructured":"Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One. 2009;4:e5727.","journal-title":"PLoS One"},{"key":"419_CR310","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/protein\/gzu041","volume":"27","author":"DC Butler","year":"2014","unstructured":"Butler DC, Snyder-Keller A, De Genst E, Messer A. Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington\u2019s disease. Protein Eng Des Sel PEDS. 2014;27:359\u201363.","journal-title":"Protein Eng Des Sel PEDS."},{"key":"419_CR311","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.btre.2014.05.008","volume":"3","author":"C Martinelli","year":"2014","unstructured":"Martinelli C, Colombo E, Piccini D, Sironi C, Pelicci PG, de Marco A. An intrabody specific for the nucleophosmin carboxy-terminal mutant and fused to a nuclear localization sequence binds its antigen but fails to relocate it in the nucleus. Biotechnol Rep Amst Neth. 2014;3:27\u201333.","journal-title":"Biotechnol Rep Amst Neth."},{"key":"419_CR312","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biom6010006","volume":"6","author":"G Simic","year":"2016","unstructured":"Simic G, Babic Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milosevic N, et al. Tau protein hyperphosphorylation and aggregation in Alzheimer\u2019s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules. 2016;6:6.","journal-title":"Biomolecules."},{"key":"419_CR313","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1021\/acschemneuro.9b00143","volume":"10","author":"P Ryan","year":"2019","unstructured":"Ryan P, Xu M, Davey AK, Danon JJ, Mellick GD, Kassiou M, et al. O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease. ACS Chem Neurosci. 2019;10:2209\u201321.","journal-title":"ACS Chem Neurosci."},{"key":"419_CR314","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1126\/science.1083911","volume":"300","author":"C Nizak","year":"2003","unstructured":"Nizak C, Monier S, del Nery E, Moutel S, Goud B, Perez F. Recombinant antibodies to the small GTPase Rab6 as conformation sensors. Science. 2003;300:984\u20137.","journal-title":"Science"},{"key":"419_CR315","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0076-6879(05)03012-0","volume":"403","author":"C Nizak","year":"2005","unstructured":"Nizak C, Moutel S, Goud B, Perez F. Selection and application of recombinant antibodies as sensors of rab protein conformation. Methods Enzymol. 2005;403:135\u201353.","journal-title":"Methods Enzymol"},{"key":"419_CR316","doi-asserted-by":"crossref","first-page":"e25197","DOI":"10.7554\/eLife.25197","volume":"6","author":"V Galli","year":"2017","unstructured":"Galli V, Sebastian R, Moutel S, Ecard J, Perez F, Roux A. Uncoupling of dynamin polymerization and GTPase activity revealed by the conformation-specific nanobody dynab. eLife. 2017;6:e25197.","journal-title":"eLife."},{"key":"419_CR317","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.yexcr.2016.03.003","volume":"342","author":"D Desplancq","year":"2016","unstructured":"Desplancq D, Freund G, Conic S, Sibler A-P, Didier P, Stoessel A, et al. Targeting the replisome with transduced monoclonal antibodies triggers lethal DNA replication stress in cancer cells. Exp Cell Res. 2016;342:145\u201358.","journal-title":"Exp Cell Res"},{"key":"419_CR318","doi-asserted-by":"crossref","first-page":"47812","DOI":"10.1074\/jbc.M307002200","volume":"278","author":"N Jendreyko","year":"2003","unstructured":"Jendreyko N, Popkov M, Beerli RR, Chung J, McGavern DB, Rader C, et al. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem. 2003;278:47812\u20139.","journal-title":"J Biol Chem"},{"key":"419_CR319","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jmb.2016.11.008","volume":"429","author":"M Cetin","year":"2017","unstructured":"Cetin M, Evenson WE, Gross GG, Jalali-Yazdi F, Krieger D, Arnold D, et al. RasIns: genetically encoded intrabodies of activated Ras proteins. J Mol Biol. 2017;429:562\u201373.","journal-title":"J Mol Biol"},{"key":"419_CR320","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1242\/bio.201410041","volume":"3","author":"M Brauchle","year":"2014","unstructured":"Brauchle M, Hansen S, Caussinus E, Lenard A, Ochoa-Espinosa A, Scholz O, et al. Protein interference applications in cellular and developmental biology using DARPins that recognize GFP and mCherry. Biol Open. 2014;3:1252\u201361.","journal-title":"Biol Open."},{"key":"419_CR321","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2008.06.005","volume":"338","author":"E Vernet","year":"2008","unstructured":"Vernet E, Konrad A, Lundberg E, Nygren P-A, Graslund T. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule. J Immunol Methods. 2008;338:1\u20136.","journal-title":"J Immunol Methods"},{"key":"419_CR322","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0022-1759(89)90080-X","volume":"125","author":"DL Berglund","year":"1989","unstructured":"Berglund DL, Starkey JR. Isolation of viable tumor cells following introduction of labelled antibody to an intracellular oncogene product using electroporation. J Immunol Methods. 1989;125:79\u201387.","journal-title":"J Immunol Methods"},{"key":"419_CR323","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0302-4598(90)80005-4","volume":"23","author":"S Kwee","year":"1990","unstructured":"Kwee S, Nielsen HV, Celis JE. Electropermeabilization of human cultured cells grown in monolayers: incorporation of monoclonal antibodies. Bioelectrochem Bioenergy. 1990;23:65\u201380.","journal-title":"Bioelectrochem Bioenergy"},{"key":"419_CR324","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1083\/jcb.114.2.277","volume":"114","author":"AK Wilson","year":"1991","unstructured":"Wilson AK, Gorgas G, Claypool WD, de Lanerolle P. An increase or a decrease in myosin II phosphorylation inhibits macrophage motility. J Cell Biol. 1991;114:277\u201383.","journal-title":"J Cell Biol"},{"key":"419_CR325","doi-asserted-by":"crossref","first-page":"C355","DOI":"10.1152\/ajpcell.1991.260.2.C355","volume":"260","author":"AK Wilson","year":"1991","unstructured":"Wilson AK, Horwitz J, De Lanerolle P. Evaluation of the electroinjection method for introducing proteins into living cells. Am J Physiol. 1991;260:C355\u201363.","journal-title":"Am J Physiol"},{"key":"419_CR326","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/cyto.990120109","volume":"12","author":"DL Berglund","year":"1991","unstructured":"Berglund DL, Starkey JR. Introduction of antibody into viable cells using electroporation. Cytometry. 1991;12:64\u20137.","journal-title":"Cytometry"},{"key":"419_CR327","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0014-4827(91)90424-S","volume":"197","author":"D Kim","year":"1991","unstructured":"Kim D, Lee YJ, Rausch CM, Borrelli MJ. Electroporation of extraneous proteins into CHO cells: increased efficacy by utilizing centrifugal force and microsecond electrical pulses. Exp Cell Res. 1991;197:207\u201312.","journal-title":"Exp Cell Res"},{"key":"419_CR328","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0014-4827(92)90146-Y","volume":"198","author":"SF Dagher","year":"1992","unstructured":"Dagher SF, Conrad SE, Werner EA, Patterson RJ. Phenotypic conversion of TK-deficient cells following electroporation of functional TK enzyme. Exp Cell Res. 1992;198:36\u201342.","journal-title":"Exp Cell Res"},{"key":"419_CR329","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1432-1033.1992.tb16866.x","volume":"205","author":"M Maccarrone","year":"1992","unstructured":"Maccarrone M, Veldink GA, Vliegenthart JF. Inhibition of lipoxygenase activity in lentil protoplasts by monoclonal antibodies introduced into the cells via electroporation. Eur J Biochem. 1992;205:995\u20131001.","journal-title":"Eur J Biochem"},{"key":"419_CR330","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0014-4827(92)90168-8","volume":"200","author":"M Glogauer","year":"1992","unstructured":"Glogauer M, McCulloch CA. Introduction of large molecules into viable fibroblasts by electroporation: optimization of loading and identification of labeled cellular compartments. Exp Cell Res. 1992;200:227\u201334.","journal-title":"Exp Cell Res"},{"key":"419_CR331","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0304-4165(94)00124-G","volume":"1243","author":"M Maccarrone","year":"1995","unstructured":"Maccarrone M, Veldink GA, Finazzi Agro A, Vliegenthart JF. Lentil root protoplasts: a transient expression system suitable for coelectroporation of monoclonal antibodies and plasmid molecules. Biochim Biophys Acta. 1995;1243:136\u201342.","journal-title":"Biochim Biophys Acta"},{"key":"419_CR332","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1128\/MCB.15.5.2600","volume":"15","author":"J Lukas","year":"1995","unstructured":"Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol. 1995;15:2600.","journal-title":"Mol Cell Biol"},{"key":"419_CR333","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1101\/SQB.1995.060.01.017","volume":"60","author":"J Wang","year":"1995","unstructured":"Wang J, Ladinsky MS, Howell KE. Molecules and vesicle coats involved in the budding of exocytotic vesicles from the trans-Golgi network. Cold Spring Harb Symp Quant Biol. 1995;60:139\u201346.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"419_CR334","doi-asserted-by":"crossref","first-page":"9182","DOI":"10.1073\/pnas.93.17.9182","volume":"93","author":"KL Sung","year":"1996","unstructured":"Sung KL, Yang L, Whittemore DE, Shi Y, Jin G, Hsieh AH, et al. The differential adhesion forces of anterior cruciate and medial collateral ligament fibroblasts: effects of tropomodulin, talin, vinculin, and alpha-actinin. Proc Natl Acad Sci USA. 1996;93:9182\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR335","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/(SICI)1097-0320(19960701)24:3<226::AID-CYTO5>3.0.CO;2-F","volume":"24","author":"GR Bright","year":"1996","unstructured":"Bright GR, Kuo NT, Chow D, Burden S, Dowe C, Przybylski RJ. Delivery of macromolecules into adherent cells via electroporation for use in fluorescence spectroscopic imaging and metabolic studies. Cytometry. 1996;24:226\u201333.","journal-title":"Cytometry"},{"issue":"Pt 14","key":"419_CR336","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1242\/jcs.110.14.1655","volume":"110","author":"GG Skouteris","year":"1997","unstructured":"Skouteris GG, Schroder CH. Cytosolic phospholipase A2 is activated by the hepatocyte growth factor receptor-kinase in Madin Darby canine kidney cells. J Cell Sci. 1997;110(Pt 14):1655\u201363.","journal-title":"J Cell Sci"},{"key":"419_CR337","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/(SICI)1097-4644(19981001)71:1<82::AID-JCB9>3.0.CO;2-Y","volume":"71","author":"SM Wang","year":"1998","unstructured":"Wang SM, Lo MC, Shang C, Kao SC, Tseng YZ. Role of M-line proteins in sarcomeric titin assembly during cardiac myofibrillogenesis. J Cell Biochem. 1998;71:82\u201395.","journal-title":"J Cell Biochem"},{"key":"419_CR338","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/(SICI)1097-4644(19991001)75:1<93::AID-JCB10>3.0.CO;2-O","volume":"75","author":"JC Wu","year":"1999","unstructured":"Wu JC, Chung TH, Tseng YZ, Wang SM. N-cadherin\/catenin-based costameres in cultured chicken cardiomyocytes. J Cell Biochem. 1999;75:93\u2013104.","journal-title":"J Cell Biochem"},{"key":"419_CR339","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1046\/j.1523-1755.2000.00085.x","volume":"57","author":"O Nakashima","year":"2000","unstructured":"Nakashima O, Terada Y, Hanada S, Yamamoto K, Kuwahara M, Sasaki S, et al. Activated STAT1 suppresses proliferation of cultured rat mesangial cells. Kidney Int. 2000;57:2249\u201357.","journal-title":"Kidney Int"},{"key":"419_CR340","doi-asserted-by":"crossref","first-page":"9390","DOI":"10.1074\/jbc.275.13.9390","volume":"275","author":"EP Rogakou","year":"2000","unstructured":"Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem. 2000;275:9390\u20135.","journal-title":"J Biol Chem"},{"key":"419_CR341","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00004872-200103000-00012","volume":"19","author":"RM Touyz","year":"2001","unstructured":"Touyz RM, Wu XH, He G, Park JB, Chen X, Vacher J, et al. Role of c-Src in the regulation of vascular contraction and Ca2+ signaling by angiotensin II in human vascular smooth muscle cells. J Hypertens. 2001;19:441\u20139.","journal-title":"J Hypertens"},{"key":"419_CR342","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0024-3205(02)01943-4","volume":"71","author":"M Rui","year":"2002","unstructured":"Rui M, Chen Y, Zhang Y, Ma D. Transfer of anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation can inhibit the apoptosis. Life Sci. 2002;71:1771\u20138.","journal-title":"Life Sci"},{"key":"419_CR343","doi-asserted-by":"crossref","first-page":"28254","DOI":"10.1074\/jbc.M604272200","volume":"281","author":"JJ Lopez","year":"2006","unstructured":"Lopez JJ, Salido GM, Pariente JA, Rosado JA. Interaction of STIM1 with endogenously expressed human canonical TRP1 upon depletion of intracellular Ca2+ stores. J Biol Chem. 2006;281:28254\u201364.","journal-title":"J Biol Chem"},{"key":"419_CR344","doi-asserted-by":"crossref","first-page":"25296","DOI":"10.1074\/jbc.M802904200","volume":"283","author":"I Jardin","year":"2008","unstructured":"Jardin I, Lopez JJ, Salido GM, Rosado JA. Orai1 mediates the interaction between STIM1 and hTRPC1 and regulates the mode of activation of hTRPC1-forming Ca2+ channels. J Biol Chem. 2008;283:25296\u2013304.","journal-title":"J Biol Chem"},{"key":"419_CR345","first-page":"493","volume":"45","author":"R Todorova","year":"2009","unstructured":"Todorova R. Estimation of methods of protein delivery into mammalian cells\u2014a comparative study by electroporation and bioporter assay. Prikl Biokhim Mikrobiol. 2009;45:493\u20136.","journal-title":"Prikl Biokhim Mikrobiol"},{"key":"419_CR346","doi-asserted-by":"crossref","first-page":"12257","DOI":"10.1074\/jbc.M110.190694","volume":"286","author":"H Zbidi","year":"2011","unstructured":"Zbidi H, Jardin I, Woodard GE, Lopez JJ, Berna-Erro A, Salido GM, et al. STIM1 and STIM2 are located in the acidic Ca2+ stores and associates with Orai1 upon depletion of the acidic stores in human platelets. J Biol Chem. 2011;286:12257\u201370.","journal-title":"J Biol Chem"},{"key":"419_CR347","doi-asserted-by":"crossref","first-page":"E355","DOI":"10.3390\/cancers11030355","volume":"11","author":"E Moeglin","year":"2019","unstructured":"Moeglin E, Desplancq D, Conic S, Oulad-Abdelghani M, Stoessel A, Chiper M, et al. Uniform widespread nuclear phosphorylation of histone H2AX is an indicator of lethal DNA replication stress. Cancers (Basel). 2019;11:E355.","journal-title":"Cancers (Basel)."},{"key":"419_CR348","doi-asserted-by":"crossref","first-page":"e48287","DOI":"10.7554\/eLife.48287","volume":"8","author":"A Alex","year":"2019","unstructured":"Alex A, Piano V, Polley S, Stuiver M, Voss S, Ciossani G, et al. Electroporated recombinant proteins as tools for in vivo functional complementation, imaging and chemical biology. eLife. 2019;8:e48287.","journal-title":"eLife."},{"issue":"3","key":"419_CR349","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41418-019-0409-3","volume":"27","author":"C Scopa","year":"2020","unstructured":"Scopa C, Marrocco F, Latina V, Ruggeri F, Corvaglia V, La Regina F, et al. Impaired adult neurogenesis is an early event in Alzheimer\u2019s disease neurodegeneration, mediated by intracellular A\u03b2 oligomers. Cell Death Differ. 2020;27(3):934\u201348.","journal-title":"Cell Death Differ"},{"key":"419_CR350","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","volume":"181","author":"C-E Wang","year":"2008","unstructured":"Wang C-E, Zhou H, McGuire JR, Cerullo V, Lee B, Li S-H, et al. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol. 2008;181:803\u201316.","journal-title":"J Cell Biol"},{"key":"419_CR351","doi-asserted-by":"crossref","first-page":"e16676","DOI":"10.1371\/journal.pone.0016676","volume":"6","author":"AL Southwell","year":"2011","unstructured":"Southwell AL, Bugg CW, Kaltenbach LS, Dunn D, Butland S, Weiss A, et al. Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. PLoS One. 2011;6:e16676.","journal-title":"PLoS One"},{"key":"419_CR352","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/hep.510300105","volume":"30","author":"M Yamamoto","year":"1999","unstructured":"Yamamoto M, Hayashi N, Takehara T, Ueda K, Mita E, Tatsumi T, et al. Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology. 1999;30:300\u20137.","journal-title":"Hepatology"},{"key":"419_CR353","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0002-9440(10)63377-9","volume":"165","author":"R Prabhu","year":"2004","unstructured":"Prabhu R, Khalap N, Burioni R, Clementi M, Garry RF, Dash S. Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone. Am J Pathol. 2004;165:1163\u201373.","journal-title":"Am J Pathol"},{"key":"419_CR354","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12896-019-0554-2","volume":"19","author":"M Flego","year":"2019","unstructured":"Flego M, Frau A, Accardi L, Mallano A, Ascione A, Gellini M, et al. Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity. BMC Biotechnol. 2019;19:64.","journal-title":"BMC Biotechnol"},{"key":"419_CR355","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1128\/JVI.78.12.6649-6656.2004","volume":"78","author":"RJ Owens","year":"2004","unstructured":"Owens RJ, Limn C, Roy P. Role of an arbovirus nonstructural protein in cellular pathogenesis and virus release. J Virol. 2004;78:6649\u201356.","journal-title":"J Virol"},{"key":"419_CR356","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/1743-422X-7-339","volume":"7","author":"J Li","year":"2010","unstructured":"Li J, Zhang Q, Wang T, Li C, Liang M, Li D. Tracking hantavirus nucleocapsid protein using intracellular antibodies. Virol J. 2010;7:339.","journal-title":"Virol J."},{"key":"419_CR357","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.15252\/embr.201643764","volume":"18","author":"L Hanke","year":"2017","unstructured":"Hanke L, Schmidt FI, Knockenhauer KE, Morin B, Whelan SP, Schwartz TU, et al. Vesicular stomatitis virus N protein-specific single-domain antibody fragments inhibit replication. EMBO Rep. 2017;18:1027\u201337.","journal-title":"EMBO Rep"},{"key":"419_CR358","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/abbs\/gmv060","volume":"47","author":"Y Liu","year":"2015","unstructured":"Liu Y, Sun L, Yu P, Li A, Li C, Tang Q, et al. Viral suppression function of intracellular antibody against C-terminal domain of rabies virus phosphoprotein. Acta Biochim Biophys Sin. 2015;47:815\u201323.","journal-title":"Acta Biochim Biophys Sin"},{"key":"419_CR359","doi-asserted-by":"crossref","first-page":"12132","DOI":"10.1128\/JVI.77.22.12132-12139.2003","volume":"77","author":"S Dekker","year":"2003","unstructured":"Dekker S, Toussaint W, Panayotou G, de Wit T, Visser P, Grosveld F, et al. Intracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses. J Virol. 2003;77:12132\u20139.","journal-title":"J Virol"},{"key":"419_CR360","doi-asserted-by":"crossref","first-page":"e01888-18","DOI":"10.1128\/JVI.01888-18","volume":"93","author":"L Wang","year":"2019","unstructured":"Wang L, Zhang L, Huang B, Li K, Hou G, Zhao Q, et al. A nanobody targeting viral nonstructural protein 9 inhibits porcine reproductive and respiratory syndrome virus replication. J Virol. 2019;93:e01888-18.","journal-title":"J Virol"},{"key":"419_CR361","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jviromet.2003.09.020","volume":"115","author":"D Blazek","year":"2004","unstructured":"Blazek D, Celer V, Navratilova I, Skladal P. Generation and characterization of single-chain antibody fragments specific against transmembrane envelope glycoprotein gp46 of Maedi-Visna virus. J Virol Methods. 2004;115:83\u201392.","journal-title":"J Virol Methods"},{"key":"419_CR362","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1128\/JVI.69.2.1044-1049.1995","volume":"69","author":"W Jiang","year":"1995","unstructured":"Jiang W, Venugopal K, Gould EA. Intracellular interference of tick-borne flavivirus infection by using a single-chain antibody fragment delivered by recombinant Sindbis virus. J Virol. 1995;69:1044\u20139.","journal-title":"J Virol"},{"key":"419_CR363","doi-asserted-by":"crossref","first-page":"23931","DOI":"10.1016\/S0021-9258(19)51027-4","volume":"269","author":"RR Beerli","year":"1994","unstructured":"Beerli RR, Wels W, Hynes NE. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem. 1994;269:23931\u20136.","journal-title":"J Biol Chem"},{"key":"419_CR364","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/sj.onc.1206299","volume":"22","author":"S Hyland","year":"2003","unstructured":"Hyland S, Beerli RR, Barbas CF, Hynes NE, Wels W. Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor. Oncogene. 2003;22:1557\u201367.","journal-title":"Oncogene"},{"key":"419_CR365","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/sj.gt.3301962","volume":"10","author":"M Figini","year":"2003","unstructured":"Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S, et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther. 2003;10:1018\u201325.","journal-title":"Gene Ther"},{"key":"419_CR366","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbrc.2007.01.052","volume":"354","author":"J-L Peng","year":"2007","unstructured":"Peng J-L, Wu S, Zhao X-P, Wang M, Li W-H, Shen X, et al. Downregulation of transferrin receptor surface expression by intracellular antibody. Biochem Biophys Res Commun. 2007;354:864\u201371.","journal-title":"Biochem Biophys Res Commun"},{"key":"419_CR367","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4161\/19420862.2015.989023","volume":"7","author":"LE Newnham","year":"2015","unstructured":"Newnham LE, Wright MJ, Holdsworth G, Kostarelos K, Robinson MK, Rabbitts TH, et al. Functional inhibition of beta-catenin-mediated Wnt signaling by intracellular VHH antibodies. mAbs. 2015;7:180\u201391.","journal-title":"mAbs."},{"key":"419_CR368","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1073\/pnas.1811360116","volume":"116","author":"A Cruz-Migoni","year":"2019","unstructured":"Cruz-Migoni A, Canning P, Quevedo CE, Bataille CJR, Bery N, Miller A, et al. Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds. Proc Natl Acad Sci USA. 2019;116:2545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"419_CR369","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41467-020-14460-4","volume":"11","author":"TA Redchuk","year":"2020","unstructured":"Redchuk TA, Karasev MM, Verkhusha PV, Donnelly SK, H\u00fclsemann M, Virtanen J, et al. Optogenetic regulation of endogenous proteins. Nat Commun. 2020;11:605.","journal-title":"Nat Commun."},{"key":"419_CR370","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/bj20020350","volume":"367","author":"N Guillaume-Rousselet","year":"2002","unstructured":"Guillaume-Rousselet N, Jean D, Frade R. Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells. Biochem J. 2002;367:219\u201327.","journal-title":"Biochem J."},{"key":"419_CR371","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.imbio.2008.12.006","volume":"214","author":"N Intasai","year":"2008","unstructured":"Intasai N, Tragoolpua K, Pingmuang P, Khunkaewla P, Moonsom S, Kasinrerk W, et al. Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9. Immunobiology. 2008;214:410\u201321.","journal-title":"Immunobiology"},{"key":"419_CR372","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1096\/fj.09-134304","volume":"24","author":"V Delanote","year":"2010","unstructured":"Delanote V, Vanloo B, Catillon M, Friederich E, Vandekerckhove J, Gettemans J. An alpaca single-domain antibody blocks filopodia formation by obstructing. FASEB J. 2010;24:105\u201318.","journal-title":"FASEB J."},{"key":"419_CR373","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1186\/bcr3585","volume":"15","author":"K Van Impe","year":"2013","unstructured":"Van Impe K, Bethuyne J, Cool S, Impens F, Ruano-Gallego D, De Wever O, et al. A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Res. 2013;15:R116.","journal-title":"Breast Cancer Res"},{"key":"419_CR374","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1096\/fj.13-242537","volume":"28","author":"I Van Audenhove","year":"2014","unstructured":"Van Audenhove I, Boucherie C, Pieters L, Zwaenepoel O, Vanloo B, Martens E, et al. Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization. FASEB J. 2014;28:1805\u201318.","journal-title":"FASEB J."},{"key":"419_CR375","doi-asserted-by":"crossref","first-page":"e0185076","DOI":"10.1371\/journal.pone.0185076","volume":"12","author":"T Hebbrecht","year":"2017","unstructured":"Hebbrecht T, Van Audenhove I, Zwaenepoel O, Verhelle A, Gettemans J. VCA nanobodies target N-WASp to reduce invadopodium formation and functioning. PLoS One. 2017;12:e0185076.","journal-title":"PLoS One"},{"key":"419_CR376","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12896-017-0360-7","volume":"17","author":"S Somplatzki","year":"2017","unstructured":"Somplatzki S, Muhlenhoff M, Kroger A, Gerardy-Schahn R, Boldicke T. Intrabodies against the polysialyltransferases ST8SiaII and ST8SiaIV inhibit polysialylation of NCAM in rhabdomyosarcoma tumor cells. BMC Biotechnol. 2017;17:42.","journal-title":"BMC Biotechnol"},{"key":"419_CR377","doi-asserted-by":"crossref","first-page":"15606","DOI":"10.1038\/s41598-018-33868-z","volume":"8","author":"E Beghein","year":"2018","unstructured":"Beghein E, Devriese D, Van Hoey E, Gettemans J. Cortactin and fascin-1 regulate extracellular vesicle release by controlling endosomal trafficking or invadopodia formation and function. Sci Rep. 2018;8:15606.","journal-title":"Sci Rep."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00419-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-020-00419-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00419-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T14:08:08Z","timestamp":1666361288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-020-00419-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":377,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00419-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"16 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"CZ is named as an inventor on patents and patent applications in the field of cancer immunotherapy owned by his previous institution (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany). CZ declares that this review article was written in the absence of any other commercial or financial relationships that could be construed as a potential conflict of interest. RM\u00d6, JR, RM and ALJM report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research received no specific Grant from any funding agency in the public, commercial, or not-for-profit sectors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}